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ABSTRACT 
Tissue hypoxia results from an inadequate supply of oxygen (O2) that compromises biologic 
functions in various tissues, including both normal and malignant. It is known that a 
heterodimeric transcription factor hypoxia-inducible factor-1 (HIF-1) mainly mediates this 
critical adaptation. It regulates the expression of more than 100 genes encoding key factors in cell 
proliferation and survival, glucose metabolism, invasion, angiogenesis and erythropoiesis.  In this 
thesis I have investigated the roles of HIF-1α in endocrine β-cells of pancreatic islets (paper I) 
and in exocrine ductal epithelial cells (paper II and III) as well as their surrounding stromal cells 
(paper IV) of pancreatic ductal adenocarcinoma (PDAC).   
 
Pancreatic islet transplantation is a biological replacement strategy for diabetes mellitus, however 
the benefits of islet transplantation are only short-term due to the lost grafts over time. Several 
strategies have been explored to improve the efficacy of islet transplantation. We previously 
reported a combination of islet preculture and recipient treatment with exendin-4 improved the 
metabolic outcome of a suboptimal number of rat islets transplanted to diabetic athymic mice. In 
paper I, we aimed to investigate mechanisms of effects of exendin-4 on islet function and 
viability in the rodent islet transplantation model with special focus on HIF-1α expression. Our 
data revealed that short-term preculture with exendin-4 followed by recipient treatment improved 
the outcome of both free and macroencapsulated islet grafts due to a larger surviving endocrine 
cell volume. Furthermore, this study has indicated for the first time that the protective effects of 
the glucagon-like peptide-1 (GLP-1) receptor agonist exendin-4 may be mediated via the HIF-1 
pathway. 
 
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant disease with fatal prognosis. It 
is characterized by a rapid progression, early metastasis, diagnosis at an advanced stage, and a 
limited response to chemotherapy and radiotherapy. Since tumour hypoxia is strongly 
associated with tumour propagation, malignant progression, and resistance to therapy, the study 
of HIF-1α has emerged a central issue in tumour physiology and cancer therapy. In paper II, we 
aimed to investigate the relationship of excess glucose, glucose reprogramming and cell 
migration in human PDAC cells with respect to HIF-1α expression. We found that excess 
glucose induced HIF-1α expression, increased ATP contents and stimulated migration in 
MiaPaCa2 pancreatic cancer cells. In addition, non-hypoxic factors contributed to this action in 
MiaPaCa2 cells as well.  
 
The drug-resistant nature of PDAC cells results in a lack of effective chemotherapies, which 
contributes to the high mortality in patients with pancreatic ductal adenocarcinoma. The 
microenvironment (such as interactions between cell surface integrins, extracellular matrix 
components and intra-tumoural hypoxia) is responsible for innate drug resistance. In order to 
screen new drugs for PDAC treatment, an in vitro model as a more predictive platform is strongly 
required in this field. In paper III we aimed to develop a 3D model of human PDAC cells, and to 
further explore mechanisms underlying the transition from 2D to 3D cultures that might be 
responsible for chemoresistance, including HIF-1 pathway. We successfully established a new 
high-throughput 3D cell culture drug screening system for pancreatic cancer, which displays 
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increased chemoresistance resulting from enhancement of ECM production, glycolysis and 
expression of miRNA, hypoxia-inducible genes as well as chemoresistance genes. Our finding 
is supporting the concept of cell adhesion mediated drug resistance in PDAC. To increase utility 
and predictive value of our 3D tumour cell model for preclinical drug discovery, in paper IV we 
generated a hetero-spheroid model with pancreatic stellate cells (PSCs) surrounding a core of 
cancer epithelial cells, as can be observed in sections from patients with PDAC. Furthermore, 
gene expression was up-regulated in hetero-spheroids of PDAC cells, including E-cadherin, β-
catenin, fibronectin, collagen I, lumican, COX2 and PPP1R1B, compared to mono-spheroids. In 
addition, we found that HIF-1α expression in hetero-spheroids was associated with the enhanced 
expression of ECM proteins, cancer stem cell marker (CD24), gene PPP1R1B (DARP-32) and 
hypoxia-inducible genes, which might alter sensitivity of cancer to chemotherapy. 
 
In conclusion, the present work demonstrates that HIF-1α is an important transcription factor 
for displaying protective effects of exendin-4 on islet grafts after islet transplantation, 
understanding the mechanism of Warburg effect in pancreatic cancer cells and describes the 
development of an organotypic in vitro culture system for PDAC, facilitating the examination 
of tumor-stroma interactions and improving predictability of drug screening system in 
pancreatic ductal adenocarcinoma.  
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1 INTRODUCTION 
1.1 Hypoxia and HIF signalling pathway 
 
1.1.1 Definition of hypoxia 
Oxygen (O2) has a central role in biology because it is used during respiration. The normal O2 
levels inside the human body vary from ~21% [corresponding to a partial pressure (PO2) of ~150 
mmHg at sea level] in the upper airway to ~1% at the corticomedullary junction of the kidney. In 
vitro, cultured cells are usually maintained in 20% O2 (95% air and 5% CO2) and this 
concentration is referred to ‘normoxia’ in spite of the fact that most cells in the human body are 
exposed to much lower O2 levels. Whatever the specific set point, complex homeostatic 
mechanisms serve to maintain the cellular O2 concentration within a narrow range in vivo [1].  
 
Hypoxia is defined as a reduction of O2 supply to the tissues of the body below physiological 
levels [2]. However, this is a relative term. Hypoxia can occur continuously, as when individuals 
ascend and remain at high altitude, or intermittently, as in individuals with sleep apnea. Hypoxia 
can be divided into an acute phase, in which rapid but transient responses are mediated through 
posttranslational modification of existing proteins, and a chronic phase, in which delayed but 
durable changes are mediated through altered gene transcription and protein synthesis. Finally, 
hypoxia can be systemic, as in the case of ascent to high altitude, or local, as in the case of 
myocardial ischemia associated with coronary artery disease [1]. 
 
Hypoxia plays essential roles in the pathophysiology of anemia, kidney, coronary artery, 
pulmonary and hematological diseases, wound healing, inflammation and cancer [1, 3 and 4]. 
However, hypoxia has also an important and beneficial role in regulating angiogenesis and 
controlling stem cell differentiation and cell fate during mammalian embryogenesis [5–7].  
 
1.1.2 The hypoxic response 
Oxygen is critical for the survival of multicellular organisms because it is used in aerobic 
metabolism, which turns carbohydrates into the energy needed to power essential cellular 
processes such as protein synthesis. Consequently, cells have to sense and respond to hypoxic 
conditions. The earliest recognized pathway is that hypoxic cells switch their primary pathway of 
energy production from oxidative phosphorylation (OXPHOS) to glycolysis. Hypoxia also 
induces erythropoietin production in renal cells (to increase haemoglobin production) and 
tyrosine hydroxylase synthesis in neural cells (involved in catecholamine production). One of the 
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most well studied hypoxic responses is production of growth factors that induce angiogenesis. 
Other hypoxia inducible genes are involved in pH homeostasis, oxygen sensing, cell death, 
genomic stability, proliferation as well as cell migration and they all aim at adapting cells to the 
hypoxic stress [8, 9]. Moreover, hypoxic tumour cells evolve to take advantage of some adaptive 
responses and to avoid others and an aggressive tumour phenotype is probably achieved through 
a stepwise selection process, in part driven by hypoxia. A number of studies have verified that 
hypoxia-inducible factors (HIFs) mediate this critical adaptation [8]. In addition, hypoxic cells 
also activate non-HIF-mediated mechanism for adaptation to hypoxic microenvironment [10–12]. 
 
1.1.3 HIF signalling pathway 
1.1.3.1 Hypoxia-inducible factors (HIFs) 
As mentioned above, HIFs is the master regulator of O2 homeostasis and it facilitates both O2 
delivery and adaptation to O2 deprivation by regulating a large number of genes involved in 
diverse processes like metabolism, apoptosis and angiogenesis [3]. HIFs are transcription factor 
consisting of an α-subunit and a β-subunit also known as the aryl hydrocarbon receptor nuclear 
translocator (ARNT). There are three isoforms of the HIF-α subunit (HIF-1α, HIF-2α and HIF-
3α) and three isoforms of HIF-1β (ARNT, ARNT2 and ARNT3), which all belong to the basic 
helix-loop-helix proteins (bHLH) of the PAS family (PER, AHR, ARNT and SIM family) [13–
17]. These subunits contain a N-terminal bHLH and two PAS domains that mediate DNA 
binding and heterodimerization, shown at figure 1 [18, 19]. HIF-1α and HIF-2α also contain an 
oxygen-dependent degradation domain (ODDD) and two transactivation domains referred to as 
the N-TAD and C-TAD (N- and C-terminal transactivation domain, respectively). The ODDD 
domain is responsible for the negative regulation of HIF-α in normoxia [20] and both TADs have 
been shown to interact with co-activators such as CBP/p300 to activate gene transcription [21, 
22]. Therefore the α-subunit is the regulatory subunit, while the β-subunit is constitutively 
expressed. Either HIF-1α or HIF-2α is able to dimerize with HIF-1β in the nucleus and binds to 
the consensus sequence 5'-(A/G) CGTG-3' present in the hypoxia response element (HRE) of O2-
controlled target genes.  
 
HIF-1α was the original HIF isoform identified by affinity purification using oligonucleotides 
from the erythropoietin locus, while HIF-2α and HIF-3α were identified by homology searches or 
screens for interaction partners with HIF-1β [13-15]. HIF-1α is expressed in most cell types, 
whereas HIF-2α shows tissue-specific expression in endothelial cells, glial cells, type II 
pneumocytes, cardiomyocytes, fibroblasts of the kidney, interstitial cells of the pancreas and 
duodenum, and hepatocytes [23]. Although HIF-1α and HIF-2α are structurally similar in their 
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DNA binding and dimerization domains and undergo similar proteolytic regulation, they have 
distinct transcriptional targets due to their different transactivation domains. It has been proposed 
that they regulate both common and unique target genes [24–26], and are differentially regulated 
depending on the duration and severity of hypoxia exposure [27]. For instance, HIF1α (and not 
HIF2α) appears to be particularly important for activating anaerobically glycolytic gene 
expression [24]. HIF-3α is also expressed in specific tissues such as adult thymus, lung, brain, 
heart, and kidney. And it is the more distantly related isoform and encodes at least one splice 
variant that is dominant-inhibitory to HIF called inhibitory PAS (iPAS) [28, 29]. HIF-1β is 
identical to a previously described constitutive nuclear protein, ARNT, which has roles in other 
transcription pathways [30]. ARNT2 and ARNT3 mainly participate in O2-independent pathways 
such as development of the hypothalamus and regulation of circadian clocks, respectively. 
 
Figure 1. Domain structures of 
human HIF transcription factors. 
The three HIF-α paralogues 
(HIF-1α, HIF-2α and HIF-3α, 
including the HIF-3α splice 
variant iPAS) and HIF-1β all 
belong to the bHLH and PAS 
protein family. HIF-α contains an 
ODDD that mediates O2-
regulated stability through the 
hydroxylation of two proline (P) 
residues and the acetylation of a 
lysine (K). The proline residues 
are conserved in HIF-2α and HIF-3α. HIF-1α and HIF-2α also contain two transaction domains (C-TAD and N-
TAD), whereas HIF-1β has only one TAD. The total number of amino acids of each subunit is marked at the end of 
the domain structure. Figure 1 is adapted from Ke Q, Costa M: Hypoxia-Inducible Factor-1 (HIF-1). Mol 
Pharmacol 2006, 70:1469–80. 
 
1.1.3.2 Regulation of HIF-1α  
HIF-1α is constitutively transcribed and translated in mammalian cells, but it has a very short 
half-life of less than 5min and is highly regulated by O2 [20, 31]. Tight regulation of the stability 
and subsequent beneficial effects of HIF-1α is mainly controlled by its post-translational 
modifications (see Figure 2), such as hydroxylation, ubiquitination and phosphorylation [32]. 
And modification of HIF-1α occurs within several domains, such as the C-terminal ODDD. 
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Figure 2. Regulation of HIF-1α 
protein by O2-dependent prolyl 
hydroxylation and proteasomal 
degradation. There are three 
hydroxylation sites in the HIF-
1α subunit: two prolyl residues 
in the oxygen-dependent 
degradation domain (ODDD) 
and one asparaginyl residue in 
the C-terminal transactivation 
domain (C-TAD). Under 
normoxic conditions, prolyl 
hydroxylation is catalyzed by the 
Fe
2+
-, O2- and 2-oxoglutarate-
dependent PHDs. The 
hydroxylated prolyl residues 
allow capture of HIF-1α by the 
von Hippel–Lindau protein 
(pVHL), leading to 
ubiquitination and subsequent 
proteasomal degradation. 
Asparaginyl hydroxylation is 
catalyzed by an enzyme termed 
as factor-inhibiting HIF (FIH) at a single site in the C-TAD. This hydroxylation prevents cofactor recruitment. In 
the absence of hydroxylation due to hypoxia or PHD inhibition, HIF-1a translocates to the nucleus, 
heterodimerizes with HIF-1β and binds to hypoxia-response elements (HREs) in the regulatory regions of target 
genes. Figure 2 is adapted from Weidemann A, Johnson RS: Biology of HIF-1alpha. Cell Death Differ 2008, 
15:621-7.  
Prolyl hydroxylation by PHDs-signaling for polyubiquitination 
Under normoxic conditions, synthesized HIF-1α is rapidly hydroxylated by specific prolyl 
hydroxylase domain proteins (PHD 1–3) on proline residues (Pro402 or Pro564) located within 
ODDD [33, 34]. The PHDs use O2 and 2-oxoglutarate (α-ketoglutarate) as substrates to create 
prolyl-hydroxylated HIF-1α and succinate. Ascorbate helps to maintain Fe in the ferrous iron; 
therefore it is required as a cofactor in the above reaction. Inactivation of the PHDs by 2-
oxoglutarate analogs such as dimethyloxalylglycine can increase the half-life of HIF-1α. In 
addition, effect of hypoxia can be mimicked by iron chelators and metal irons (such as Co
2+
) 
because PHDs contain Fe
2+
 in their catalytic centers. Cobalt appears to not only bind HIF-1α 
but also is thought to compete with or displace Fe
2+
 from the Fe
2+
 binding site in the PHD [35]. 
In addition to the enzymatic inhibition of the PHDs, hypoxia induces a paradoxical burst of 
reactive oxygen species (ROS), which converts Fe
2+
 to Fe
3+
. As a consequence, this alteration 
inhibits PHD activity and promotes HIF-1α stabilization [36–38]. This implies that hypoxia has 
both direct and indirect roles on PHD function. 
 
Due to the O2-dependent activity of PHDs, they are considered as oxygen sensors, monitoring the 
progressive increase in HIF-1α abundance. Moreover, PHD2 was particularly demonstrated to be 
the most important isoform in oxygen sensing, since only knockdown of PHD2 is sufficient to 
stabilize HIF-1α protein levels under normoxic conditions [31, 39, 40]. It had been demonstrated 
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PHD2 localized primarily in the cytoplasm, whereas PHD1 was in the nucleus and PHD3 was in 
both compartments [41]. Despite its primary localization in the cytoplasm, PHD2 is able to 
shuttle between the cytoplasm and the nucleus, thereby contributing to HIF-1α degradation in 
both compartments. Interestingly, expression of PHD2 is reciprocally up-regulated by HIF-1α 
proteins under hypoxia and this may represent a way by which HIF-1α self-regulates its 
expression [40, 42].   
 
Polyubiquitination by pVHL-signaling for O2-dependent degradation 
Once HIF-1α is hydroxylated by PHDs, the von Hippel-Lindau tumour suppressor protein 
(pVHL) then captures HIF-1α. The pVHL is the recognition component of an E3 ubiquitin ligase 
complex that includes Elongin C, Elongin B, cullin-2, and RBX1 (ring box protein-1) [43]. 
Binding of HIF-1α to this multiprotein E3 complex causes polyubiquitination of HIF-1α, 
eventually leading to its degradation by 26S proteasome [44, 45]. In hypoxia however, enzymatic 
activity of PHDs is inhibited, HIF-1α protein then escapes the VHL capture and proteasomal 
degradation.  Furthermore, mutations in VHL gene that are associated with renal cell carcinoma 
and sporadic tumours prevent this ubiquitin, resulting in an accumulation of HIF-1α and 
continuous over-expression of hypoxia-inducible genes [46]. 
The pVHL E3 ligase complex predominantly localized in the cytoplasm and can shuttle back and 
forth between the nucleus and cytoplasm, leading to HIF-1α degradation in both compartments 
[47, 48].  Importantly, pVHL mutants that interfere with its nuclear-cytoplasmic trafficking can 
no longer regulate hypoxia-inducible genes [48]. In addition, pVHL itself is also tightly regulated 
by the ubiquitin-proteasome pathway, which is mediated by the E2-endemic pemphigus foliaceus 
(EPF) ubiquitin carrier protein (UCP). EPF-UCP is an E2 ubiquitin-conjugating enzyme [49]. A 
co-expression of UCP and HIF-1α correlating with decreased pVHL was observed not only in 
different human normoxic cell lines in a cell line–dependent manner, but also in non-hypoxic 
area of human primary and metastatic tumours, such as liver, colon and breast tumours [50]. This 
may provide an explanation for the elevated levels of HIF-1α that are observed in non-hypoxic 
regions of such tumours. 
 
In addition, spermidine/spermine-N
1
-acetyltransferase (SSAT)2 was identified as one of HIF-1α 
binding partners by a yeast two-hybrid screen [51]. SSAT2 binds to the PAS A-subdomain of 
HIF-1α (residues 81–200) and promotes its O2-dependent ubiquitylation/degration by stabilizing 
the interaction of pVHL and elongin C (see Figure 3). Although mutation in SSAT2 conservative 
residues (Ser82 and Thr83) interferes with its acetyltransferase activity on physiological substrate 
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of SSAT2, it doesn’t eliminate the ability of SSAT2 to promote HIF-1α degradation [51]. 
Thereby, the inhibitory activity of SSAT2 on HIF-1α is believed to result from the combined 
effect of its acetyltransferase activity and physical interactions with HIF-1α, pVHL and elongin 
C.  
 
 
Figure 3. The O2-dependent and O2-independent pathways for HIF-1α ubiquitination and degradation. Left, 
SSAT2 is required for O2- and PHD2/VHL-dependent ubiquitination of HIF-1α. Right, SSAT1 is required for O2-
independent and RACK1-dependent ubiquitination of HIF-1α in response to treatment with the HSP90 inhibitor 
17-AAG. In both cases, ubiquitination is mediated by recruitment of the Elongin C ubiquitin-ligase complex, 
which also includes Elongin B, RBX1, cullin-2, and an E2 ubiquitin carrier protein (B/R/C/E2). Figure 3 is 
adapted from Baek JH, Liu YV, McDonald KR, Wesley JB, Hubbi ME, Byun H, Semenza GL: 
Spermidine/spermine-N1-acetyltransferase 2 is an essential component of the ubiquitin ligase complex that 
regulates hypoxia-inducible factor 1alpha. J Biol Chem 2007, 282:23572–80. 
 
Polyubiquitination mediated by RACK1 pathway for O2-independent degradation  
In addition to the pVHL mediated HIF-1α degradation, the O2-independent degradation pathway 
also has an important role in controlling HIF-1α levels. It involves the heat-shock protein 90 
(HSP90) and receptor of activated protein C kinase (RACK1), which compete for binding to 
HIF-1α [52]. RACK1 homodimerizes and recruits Elongin C and other components of the E3 
ligase complex to HIF-1α in an O2-independent manner, leading to HIF-1α ubiquitylation and 
26S proteasome-dependent degradation. HSP90 competes with RACK1 for binding to the PAS 
A-subdomain of HIF-1α and inhibition of Hsp90 causes O2- and pVHL-independent HIF-1α 
degradation [53]. RACK1-HIF-1α binding is dependent upon the presence of SSAT1, which 
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stabilizes the interaction between these two proteins, and SSAT1 acetyltransferase activity is 
required in this process (see Figure 3). Although homologous proteins SSAT1 and SSAT2 
(described earlier) both bind to and promote HIF-1α ubiquitylation, they do so by completely 
different and complementary molecular mechanisms: SSAT2 binds to the PAS A-subdomain of 
HIF-1α and promotes O2- and pVHL-dependent regulation, whereas SSAT1 binds to the PAS B-
subdomain (residues 201-329) and promotes O2-independent, RACK1-dependent HIF-1α 
degradation [53].  
 
The RACK1 pathway is also regulated by calcium through the activity of calcineurin, a 
calcium/calmodulin-dependent and serine/threonine-specific protein phosphatase. Calcineurin 
dephosphorylates RACK1 in a calcium-dependent manner, thus promotes HIF-1α expression by 
blocking RACK1 dimerization and inhibiting RACK1-mediated HIF-1α degradation [54]. Thus, 
it indicates that intracellular calcium levels can regulate HIF-1α expression by modulating 
calcineurin activity and RACK1 dimerization. 
 
Asparagine hydroxylation by FIH-1-preventing CBP/p300 binding 
Under different post-translational modifications described above, HIF-1α protein is stabilized but 
it is not sufficient for full transcriptional activation of HIF-1. A second level of HIF-1α regulation 
occurs in the nucleus through the hydroxylation of an asparagine residue at the C-terminal end of 
HIF-1α [55]. HIF-1α contains two transactivation domains, N-TAD and C-TAD, employing 
recruitment of coactivators such as p300 and its paralogue CREB-binding protein (CBP), steroid 
receptor coactivator-1, and the transcription intermediary factor 2 [56–59]. The CBP/p300 is 
essential for linking transcription factors with coactivator complexes and the basal transcriptional 
machinery, and is  thus indispensable for robust transcriptional activation. Moreover, CBP/p300 
proteins have histone acetyltransferase activity that is necessary for chromatin modification prior 
to transcription.  
 
FIH-1 (factor inhibiting HIF-1) is another α-ketoglutarate-dependent dioxygenase that 
hydroxylates Asn803 and thereby prevents interaction of HIF-1α C-TAD with the coactivators 
CBP/p300 [60–62]. In contrast to the prolyl hydroxylation that enables protein–protein 
interaction, the asparaginyl hydroxylation prevents protein recruitment. Because FIH‐1 also 
requires O2 for catalytic activity, C-TAD of HIF-1α remains unmodified under hypoxia and can 
efficiently interact with CBP/p300 to activate transcription of HIF-1 target genes [61]. 
Replacement of Asn803 with alanine permits coactivator binding with HIF-1α in normoxia [55]. 
Utilization of O2 as a substrate allows FIH-1 to serve as a second O2 sensor. The estimated Km 
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values of FIH-1 and the PHDs for O2 were first reported to be approximately 90 and 250 mM, 
respectively [63, 64]. Although these values were determined in vitro using relatively short 
peptides as substrates, they do provide a guide as to the O2 sensitivity of these enzymes within 
cells. Thus as the severity of hypoxia increases, the PHDs would be inactivated first, maximal 
activation of the HIF-1 pathway requires more severe hypoxia to inactivate FIH-1 [65]. Indeed, 
overexpressed FIH-1 can still play a catalytic effect at 0.2% O2 concentration, whereas the PHDs 
were inactive under the same conditions [66].  
 
Figure 4. Hypothesized 
sequential activation of 
HIF-1α in gradients of 
hypoxia: based on the in 
vitro derived Km values of 
PHDs and FIH for O2, as 
O2 concentrations drop, the 
PHDs lose catalytic 
activity first due to their 
weaker affinity for O2, 
increasing HIF-1α stability, 
while C-TAD activity is 
still repressed due to the 
hydroxylation of Asp803 
by FIH-1. At lower O2 
tensions, catalytic activity 
of FIH-1 is reduced leading 
to the full transcriptional 
activation of HIF-1. Figure 
4 is adapted from Kizaka-
Kondoh S, Tanaka S, 
Harada H, Hiraoka M: The 
HIF-1-active microenvironment: an environmental target for cancer therapy. Adv Drug Deliv Rev 2009, 
61:623–32. 
 
The transcription of FIH-1 itself is not affected by O2 concentration and FIH-1 does not influence 
HIF-1α stability. FIH-1 is mainly located in the cytoplasm even under hypoxia, but a small 
portion resides in the nucleus as well [41]. Like PDHs, FIH-1 also requires 2-oxoglutarate, Fe
2+
, 
ascorbate and O2 for catalysis of hydroxylation. However pyruvate and tricarboxylic citric acid 
cycle intermediates, such as isocitrate, oxaloacetate, succinate, and fumarate, inhibit PHD2, but 
apparently do not inhibit FIH-1 [67–70].  
 
Phosphorylation by MAPK-enhancing transactivation 
Despite hydroxylases play a central role in sensing O2 tension and regulating HIF-1α, mitogen-
activated protein kinase (MAPK) signaling is required for the transactivation activity of HIF-1α 
[71, 72]. It has been shown that MEK-1/p42/p44 MAPK pathway activates the transactivational 
ability of HIF-1α, but does not regulate its stabilization and DNA binding activity [71]. MAPK 
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has been correlated with C-TAD activity as enhanced activation of MAPK stimulates both HIF-
1α and p300 and conversely inhibition of MAPK restricts transcription by disruption of HIF-C-
TAD/p300 interaction [72]. Moreover, phosphorylation of two distinct serine residues (Ser-
641/643) inside the inhibitory domain of HIF-1α by p42 MAPK promotes the nuclear 
accumulation and activity of HIF-1α by blocking its chromosome maintenance region 1-mediated 
nuclear export [73]. 
 
In addition to the post-translational modification of HIF-1α described above, the small ubiquitin-
like modifier (SUMO) modification of HIF-1α might contribute to repressing transactivation 
[32], though a varied outcome of hypoxia-induced SUMOylation in HIF-1α has been reported 
[74–77]. For example, SUMOylation of HIF-1α has been suggested to both increase HIF-1α 
stability and transcriptional activity [74, 75], however in other studies, it has been suggested to 
decrease activity and enhance pVHL-mediated ubiquitination [76, 77]. Moreover, S-nitrosation 
on cysteine 800 of HIF-1α has been shown to increase its transactivation via enhancement of its 
interaction with CBP/p300 [78]. However, another quantitative interaction study with purified 
proteins and peptides demonstrated a significant decrease in p300 binding upon Cys800 S-
nitrosylation [79]. 
 
Additionally, translation level of HIF-1α is modulated by many growth factors and cytokines, 
such as insulin (INS), insulin-like growth factor-2 (IGF-2), tumour necrosis factor-α (TNF-α), 
epidermal growth factor (EGF) and interleukin-1β (IL-1β), resulting in the HIF-1α accumulation 
under either hypoxia or non-hypoxia conditions [80–82]. Although complex and cell-type 
dependent, it has been suggested that activation of phosphatidylinositol 3-kinase (PI3K) or 
MAPK pathways plays a role in the phosphorylation of HIF-1α and subsequent protein 
stabilization [81–83].  
 
1.1.3.3 HIF-1 mediated hypoxic response  
As described above, PHDs and FIH-1 are repressed in the absence of O2, thereby HIF-1α protein 
is able to accumulate and translocate into the nucleus, where it dimerizes with HIF-1β and 
activates the transcription of a number of target genes displaying an HRE motif [83]. It has been 
found that HIF-1 is expressed in all nucleated cells of metazoan species and functions as a master 
regulator of oxygen homeostasis [1]. It regulates the expression of more than 100 genes encoding 
key factors in cell proliferation and survival, glucose metabolism, invasion, angiogenesis and 
erythropoiesis [81–84] (see Figure 5). Therefore, hypoxia and HIF-1 have been correlated with 
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the embryonic development and both protective responses and pathogenesis in varies diseases 
such as organ transplantation and cancer, respectively [81].  
 
Figure 5. Transcriptional targets of HIF-1. A representation of the increasing number of genes is modulated by HIF-
1, which are involved in various adaptive processes in response to hypoxia.  Figure 5 is adapted from Zhong H, 
Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu M, Simons JW, Semenza GL: Modulation of hypoxia-
inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-
kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells : implications for tumor angiogenesis and 
therapeutics. Cancer Res 2000, 60: 1541-45. 
 
1.2 Pancreatic diseases and therapy 
1.2.1 Cell components of the pancreas   
Pancreas is the second largest gland in the human body and it is functionally divided into an 
endocrine portion (about 1-2% of the total weight of the pancreas) and an exocrine portion (about 
80%) [85, 86]. The lobules are connected by connective tissue septa that contain the blood 
vessels, nerves, lymphatics, and excretory ducts (constituting about 18% of this organ). 
 
The part of pancreas with endocrine function is made up of about 1.5 million cell clusters entitled 
the islet of Langerhans (see Figure 6) that are scattered throughout the exocrine tissue [86, 87]. It 
consists of glucagon-producing α cells, insulin-producing β-cell, somatostatin-producing δ-cell, 
ghrelin producing ε-cell and pancreatic polypeptide-producing PP-cell, which work together to 
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regulate the glucose metabolism. The size of the islets varies between approximately 20-250 μm 
in diameter with the majority of islets being <100 μm [86, 87].  
 
As the most abundant and important cell type, β-cells comprise 65-80% of the islets of 
Langerhans, sensing the glucose level in the blood and secreting insulin to counteract 
hyperglycemia [88]. Besides insulin, islet amyloid polypeptide (also known as amylin) is also 
produced by β-cells, which plays a role in glucose homeostasis [85, 89]. The second most 
common cell type in the islet is α-cell (15–20% of islet mass) that produces glucagon as a 
negative regulator of insulin, which mainly stimulates glycogenolysis and gluconeogenesis in the 
liver. Besides endocrine cells, the islet of Langerhans also contains endothelial cells, nerves, 
fibroblasts and dendritic cells [85]. Particularly, islets are highly vascularized mini organs that 
receive 5-10 times higher blood flow than the exocrine part of the pancreas [90]. β-cells are able 
to consume large amounts of O2 serving for the high demand of mitochondrial respiration during 
insulin secretion [91], thereby they are sensitive to hypoxic conditions that may occur during islet 
isolation and after transplantation.  
 
Figure 6. The figure represents exocrine and 
endocrine tissues in pancreas. It is from Pandol SJ: 
The Exocrine Pancreas. San Rafael (CA): Morgan & 
Claypool Life Sciences 2010. 
 
The exocrine portion of pancreas has ducts 
that are arranged in clusters of acinar cells 
(known as acini) (see Figure 6). Acinar cells 
are tall, pyramidal or columnar epithelial 
cells, which are specialized to synthesize, store, and secrete digestive enzymes. With their broad 
bases on a basal lamina, apices of acinar cells converge on a central lumen that is the origin of the 
secretory duct. In response to distension and/or food in stomach and duodenum, digestive 
enzymes, H2O and NaHCO3 are secreted into the duodenum through the pancreatic ductal 
system. Tight junctions between acinar cells form a band around the apical aspects of the cells 
and act as a barrier to prevent passage of large molecules, such as the digestive enzymes. The 
junctional complexes also provide for the paracellular passage of H2O and ions [92].  
 
The duct cell epithelium consists of cells that are cuboidal to pyramidal and contain the abundant 
mitochondria necessary for ATP-dependent ion transport. The lumen of the acinus also contains 
the centroacinar cell, which is unique to pancreas. This cell has ductal cell characteristics but is 
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also likely a progenitor for different cell types for the pancreas. The duct cells as well as the 
centroacinar cells produce carbonic anhydrase, which is important for their ability to secrete 
bicarbonate [92].  
 
Another cell type of exocrine pancreas that is becoming important because of its role in 
pathologic states is the pancreatic stellate cell (PSC) [93, 94]. In normal pancreas, this star-shaped 
cell represents approximately 4% of the resident cells and is located in the periacinar and 
interlobular space. And quiescent PSCs can be identified by the presence of vitamin A-containing 
lipid droplets in the cytoplasm [95]. The role of PSCs in normal tissue is probably to lay down 
the basement membrane to direct proper formation of the epithelial structures. Their roles in 
pathologic states, such as chronic pancreatitis and pancreatic cancer, have been of considerable 
interest. PSCs participate in disease pathogenesis after transforming from a quiescent state into an 
“activated” state (also known as a “myofibroblastic” state). Characteristic features of this 
transition include an enhancement in the production of extracellular matrix (ECM), including 
type I and III collagens, laminin, fibronectins, as well as matrix metalloproteinases (MMPs) and 
tissue inhibitors of metalloproteinases. Other important features of activation include loss of 
vitamin A lipid droplets, proliferation, increased expression of α-smooth muscle actin (α-SMA) 
and up-regulation of various cytokines and growth factors, such as TGF-β1, PDGF and vascular 
endothelial growth factor (VEGF), etc [93, 94]. Sustained activation of PSCs has an increasingly 
appreciated role in the fibrosis that is associated with chronic pancreatitis and with pancreatic 
cancer [96]. Particularly, the activated PSCs are emerging as a key participant in both the rate of 
growth of the cancer and the development of resistance to chemotherapy [93]. 
 
1.2.2 Diabetes mellitus and pancreatic islet transplantation  
1.2.2.1 Type 1 diabetes mellitus 
The different forms of diabetes mellitus are characterized by deficient insulin release in relation 
to the insulin demand. According to World Health Organization, there are approximately 347 
million adults with diabetes worldwide. Type 2 diabetes mellitus is the most common type of this 
disease, comprising 90% of diabetic patients, and is largely the result of excess body weight and 
physical inactivity. It is characterized by a combination of impaired insulin production from the 
pancreatic β-cells and insulin resistance in peripheral tissues [97]. Although the incidence of type 
2 diabetes is higher than type 1, the latter remains the most common chronic condition in 
children. Type 1 diabetes is primarily due to autoimmune-mediated destruction of β-cells, 
resulting in absolute insulin deficiency. Patient with type 1 diabetes require life-long intake of 
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exogenous insulin to control blood glucose levels and to prevent ketoacidosis [97, 98]. And many 
of them develop complications related with cardiovascular disease, nephropathy, neuropathy and 
retinopathy, which account for most of the increased morbidity and mortality associated with the 
disease [98]. Moreover, some of patients could develop resistance to insulin therapy, who may 
experience repeated hypoglycaemia or diabetic ketoacidosis. Transplantation of pancreas or 
pancreatic islets could provide cure of diabetes or improvement of blood glucose control in such 
recipients. 
 
1.2.2.2 Pancreatic islet transplantation 
Pancreatic islet transplantation is a biological replacement strategy for treating selected patients 
with frequent hypoglycemic events or severe glycemic lability. It is considered less invasive with 
a minor operation and thus the patient will not have severe complications as compared to the 
major surgery in whole pancreas transplantation. Although significant progress has been made in 
the islet transplantation field, many obstacles still remain to the application of islet transplantation 
in the clinic. Two of the most important limitations are severe shortage of donor and the currently 
inadequate treatments for preventing islet rejection [99, 100].     
 
Clinical islet transplantation 
Modern clinical experience with islet transplantation can be dated to 1977 when Najarian and his 
colleagues injected approximately 50,000 “impure” islets into a diabetic patient’s intraperitoneal 
space and reported some decrease in the blood glucose [101]. Over the next decade, optimization 
of the technique of islet isolation and use of immunosuppressive drugs with less deleterious side 
effects became focal points in the field [102, 103]. Until 2000, interest in islet transplantation was 
reawakened after Shapiro et al. reported successful outcome in seven patients who all became 
insulin independent and still being fully functional during the one-year follow-up. Their novel 
approach utilized freshly isolated islets from multiple donors injected into the main portal vein in 
the liver on C-peptide negative type 1 diabetic patients with several episodes of hypoglycemic 
unawareness, using a steroid-free immunosuppressive protocol [104]. The success achieved in the 
Edmonton protocol transformed islet transplantation from an experimental procedure to a true 
alternative to conventional diabetes therapies in patients with glycemic lability. Clinical protocols 
to optimize islet survival and function in post-transplantation improved dramatically with the 
introduction of the Edmonton protocol [105]. Results of the Collaborative Islet Transplant 
Registry published in 2009 [106] reported, after achievement of insulin independence, 70% of 
islet-alone recipients retained it at 1 year after transplantation, as did 55% at 2 years, 45% at 3 
years, and 36% at 4 years. Despite the success rate declined in long-term follow-up, islet 
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transplantation affords C-peptide positivity, nearly normal hemoglobin A1c levels, fewer 
episodes of hypoglycemia, reduction of diabetic complications [107, 108], and improved quality 
of life [109], thus showing an emerging role in contemporary type 1 diabetes management.  
 
Obstacles of success in islet transplantation 
Several reasons cause the loss of graft function with time: loss of islet mass during isolation and 
culture, loss of islet graft immediately after transplantation by instant blood mediated 
inflammatory response (IBMIR) [110] and during the first week after transplantation by the 
prolonged inflammatory process as well as the shortage of O2 and other nutrients, and gradual 
loss of the surviving islets with time due to chronic rejection caused by reoccurrence of 
autoimmunity [111]. Moreover, the immunosuppressive drugs are not only beneficial to islet 
graft in preventing rejection, but also harmful to them due to toxic effects [112].  
 
Generally about 50–70% of pancreatic islet cells undergo apoptosis during isolation, culture, and 
the peritransplant period [87]. During isolation, islets are separated from their pervious 
nourishing microenvironment and subjected to devascularization, denervation, and hypoxia. A 
culture period following isolation may provide the islets with a needed recovery prior to 
transplantation, whereas data from both human and mice islet transplantation suggest that fresh 
isolated islets are more effective than cultured islets at reserving hyperglycemia [113, 114]. 
Indeed, fresh islets have shown a higher O2 and adenosine triphosphate (ATP) contents than 
cultured islets [113].  
 
Clinically, islets were injected via portal vein but more than 50% of islet mass was destroyed 
within one hour [115] due to the damaging rapid clotting process termed IBMIR [110]. Once 
transplanted, islets require rapid revascularization for survival and proper glucose sensing, and at 
this time point, they also face allorejection, recurrent autoimmunity, inflammatory and metabolic 
stress, which all lead to the early islet graft loss [87]. Therefore, the periods immediately after 
islet isolation and transplantation are particularly crucial for long-term survival of islets.  
 
Several immunosuppressive drugs are found to be associated with significant toxicity and thereby 
cause a number of adverse effects [116] in islet recipients, including painful mouth ulceration, 
peripheral oedema, proteinuria, hypercholesterolaemia and hypertension. In addition, they also 
increase the risk for infection and certain malignancies as designed to weaken the immune 
response in recipients. Therefore, several strategies to reduce immunosuppressive drugs have 
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been studies, such as induction of peripheral tolerance and development of immunopretective 
encapsulation [117–119]. 
 
Strategies to improve outcome of islet transplantation 
There are many strategies to improve outcome of islet transplantation. In this thesis, I focused 
two aspects: enhancement of islet robustness by drugs and protection of islets from rejection by 
immunopretective encapsulation.  
 
1) Usage of drugs to increase islet robustness: In order to improve the transplantation efficiency, 
a variety of approaches, such as anti-inflammatory, anti-apoptosis, metabolic and growth 
stimulation and immunomodulation have been investigated. Exendin-4, a glucagon-like peptide-1 
(GLP-1) receptor agonist, is currently used in the management of type 2 diabetes and has shown 
to improve the outcome of islet transplantation [120–123]. It has a number of effects including 
glucose-dependent stimulation of insulin secretion [124], the suppression of glucagon secretion 
[125], the slowing of gastric emptying, the inhibition of food intake, and the modulation of 
glucose trafficking in the peripheral tissues. With regard to islet transplantation, the special 
interest is its ability to inhibit β-cell apoptosis and increase β-cell proliferation [126–128]. When 
clinical protocols using exendin-4 in islet transplantation are being designed, it is important to 
discuss the optimal treatment period. The initial short period following islet transplantation has 
been considered as a critical time to preserve the quantity and quality of islet. In recent clinical 
trials, exenatide (recombinant GLP-1 analogue) treatment combined with tumour necrosis factor 
(TNF) receptor antagonist, etanercept, from the time of initial islet transplantation showed 
promising effects for engraftment and long-term graft survival [123, 129, 130]. However, nausea 
and vomiting were major adverse effects of exendin-4 therapy that limited patient compliance for 
long-term administration [129, 130]. Pretreatment of isolated islets prior to transplantation could 
be also an effective way to improve transplantation outcome. One advantage of islet preculture 
would reduce the dosage of drug given on the patient systemically and thus it is a safer option. In 
an earlier study, we demonstrated that a combination of islet preculture and recipient treatment 
with exendin-4 improves the metabolic outcome of a suboptimal number of rat islets transplanted 
to diabetic athymic mice [121]. However, that study was not designed to compare the individual 
impact of islet preculture or recipient treatment on graft outcome. In this thesis, I compared the 
effect of exendin-4 treatment on different aspects before and after islet transplantation (Paper I).  
 
Current methods of islet preparation cause hypoxic stress that has been considered as one of the 
major contributors to β-cell death. Animal studies have demonstrated that about 80% of 
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intraportally injected islets are hypoxic at 1 day after transplantation [131]. Revascularization of 
islets takes at least 1 week, but the impaired vascular density does not seem to recover fully [132, 
133]. Adaptive responses to hypoxia are triggered following the expression HIF-1α and induce a 
series of genes, for example in glucose metabolism adaptation, angiogenesis, apoptosis, and cell 
growth [81, 82, and 83]. It has been reported that HIF-1α is an important molecule to regulate β-
cell function in pancreatic islets even in normoxic conditions [134]. A recent report also showed 
that decreased apoptosis is caused by HIF-1α, resulting in increased β-cell mass in post-
transplantation [135]. These findings suggest that HIF-1α is a protective factor and is required for 
successful islet transplant outcomes. Therefore, anti-apoptotic effect of exendin-4 was studied in 
paper I with a special focus on HIF-1α expression in isolated islets.  
 
2) Usage of immunoprotective devices for islet transplantation: Encapsulation of islets is 
attractive methods in order to avoid chronic usage of immunosuppressive drug. There are 
different strategies for cell encapsulation involving enclosure of cellular groups within an 
immunoprotective biomaterial, such as micro- and macro-encapsulation devices. 
Microencapsulation is the encapsulation of single or small groups of islets in a gel capsule [136], 
which offers the advantage of increased O2 and nutrient transport due to the large surface area-to-
volume ratio. Major limitations of micro-encapsulation are insufficient encapsulation and 
instability of the capsule, which can lead to graft rejection over time. This can be overcome by 
macro-encapsulation of the graft inside diffusion chambers such as the TheraCyte
TM
 (TheraCyte 
Inc, Irvine, CA, USA) device used in this thesis. The advantages of this device are that it requires 
minor surgery and can be retrieved if needed. 
 
This planar diffusion chambers is shaped like a teabag (see Figure 7) and composed of a double 
membrane of polytetrafluoroethylene. The inner membrane (pore size: 0.45μm) provides 
immunoisolation that enables the diffusion of nutrients and O2, whereas the outer membrane 
(pore size: 5μm) facilitates angiogenesis. In an xenotransplantation study, neonatal porcine islets 
within TheraCyte™ device transplanted subcutaneously survive and reverse diabetes for up to 16 
weeks in diabetic autoimmune non-obese diabetic mice [118]. More recently, a study using an 
allogeneic rat model has showed the TheraCyte™ device protects the allografts also in 
immunized recipients [119] that further highlights the potential for using macro-encapsulation to 
avoid immunosuppressive therapy in clinical islet transplantation.  
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Figure 7. The TheraCyte
TM 
device is a thin membrane bound polymeric 
chamber, which protects allogeneic cells from rejection by the recipient and, 
when implanted subcutaneously, induces the development of blood capillaries 
close to the membranes. This vascularization feature provides a rich blood 
supply to nourish the tissues within the membranes, aids in the communication 
of implanted cells with the host and assures rapid uptake of therapeutic 
molecules. (http://www.theracyte.com/TheTechnology.htm; TheraCyte, Inc.) 
However, the major drawback in macro-encapsulation is the 
limitation of O2 diffusion and nutrient transport. Until such an 
implantable device is revascularised, islet graft is exposed to 
hypoxia and other nutrient deprivation due to a poor blood supply 
and the superficial location of the transplant, which is associated 
with a risk of mechanical stress and damage to the graft. 
Proliferation of fibroblasts, occurring within the devices one month 
after implantation, is another limitation of macroencapsulation for a long-term islet graft survival. 
Our previous studies showed that it would need two-three months to get well vascularization of 
the empty membrane [137], and a preimplantation of the TheraCyte™ device three months 
before the islet transplantation could significantly reduce curative doses of macroencapsulated 
rat islets to the same dose as non-encapsulated islet transplantation [138]. It is still of great 
interest that any drug can improve graft outcome in the model of the macroencapsulated islet 
transplantation. In paper I, I investigated the effects of exendin-4 treatment on the 
macroencapsulated islet transplantation in rodent models.  
 
1.2.3 The tumour microenvironment in pancreatic cancer  
Pancreatic ductal adenocarcinoma (PDAC) is associated with a 5-year survival rate of less than 5% 
and a median survival of 6 months after diagnosis, thereby exhibiting the poorest prognosis of all 
solid tumours [139, 140]. This dismal prognosis is a result of the late diagnosis of the disease, the 
lack of biomarkers allowing early screening, the early metastatic dissemination and ultimately the 
resistance to systemic therapies. Known risk factors for the disease include cigarette smoking, 
chronic and hereditary pancreatitis, late onset diabetes mellitus and familial cancer syndromes 
[141]. Although target therapies have seen significant advances in the treatment for many tumour 
types, including melanoma, lung and colorectal cancer [142], similar success has not occurred in 
PDAC, which remains a lethal disease. Gemcitabine, the current standard-of-care 
chemotherapeutic was approved mainly on the basis of patient benefit and produced only a modest 
increase in survival [143, 144]. One explanation for the poor response of patients to systemic 
therapies was provided in an accurate PDAC mouse model by the demonstration that 
chemotherapies are poorly delivered to PDA tissues because the presence of the dense stromal 
  24 
matrix correlated with a deficient vasculature [145]. A deeper knowledge of the underlying 
mechanisms is the key to better understand the tumour progression and metastasis as well as to 
identify novel therapeutic strategies capable of overcoming the chemoresistance in PDAC. 
 
1.2.3.1 The stromal microenvironment and chemoresistance 
One of the most prominent histological features of PDAC is the presence of an abundant tumour 
stroma [146], which displays an extensive stromal reaction accounting for up to 90% of the 
tumour volume. The stromal microenvironment is a complex structure composed of ECM 
proteins, activated fibroblasts and PSCs, inflammatory cells as well as blood and lymphatic 
vessels that distort the normal architecture of pancreatic tissue. It is not a static entity but is 
constantly changing in composition especially in the progression from pre-neoplastic pancreatic 
intraepithelial neoplasia (PanIN) to invasive PDAC. Early PanIN lesions may be associated with 
small amounts of normal stroma surrounding the normal pancreatic ducts from which the PanINs 
arise. By contrast, with PanIN III lesions there may be the beginning of enhanced stroma 
formation, and progression to invasive carcinoma is often associated with a readily evident 
increase in stroma formation that ultimately results in extensive stroma. Often, there is an 
associated inflammatory infiltrate [146]. 
 
Interactions between cancer cells and stromal cells and extracellular matrix have been proposed 
to stimulate the extensive fibrotic, desmoplastic reaction. Cancer cell derived growth factors 
[146–148], such as fibroblast growth factors (FGFs), TGF-β, IGF-1, hepatocyte growth factor 
(HGF), PDGF-BB, and EGF become sequestered within the stroma, which thus acts as a storage 
site for these factors. The invading cancer cells produce matrix metalloproteinases (MMPs) that 
release these growth factors. Upon activation by growth factors, cytokines or oxidant stress, PSCs 
transform into a myofibroblast-like phenotype and promote fibrogenesis and ultimately may 
create a highly desmoplastic, hypovascular and hypoxic tumour microenvironment [149, 150].  
Moreover, there is an altered gene expression profile in the cancer-associated stroma, including 
altered integrin expression that may promote cancer cell motility, increased expression of 
cyclooxygenase-2 (COX-2), PDGF, VEGF-A, collagen I, WNT5a and HIF-1α that enhance 
stromal neo-vascularization, promote cancer cell growth and resistance to hypoxia [151–156]. 
Therefore, PSCs have emerged as key players in PDAC promotion and progression, as described 
above [93, 94].  
 
In addition, the stromal component has been suggested to control drug sensitivity in cancer [157]. 
In vitro, PSCs induce PDAC cancer cell resistance to both gemcitabine and radiation [158]. This 
  25 
effect may partly be mediated by PSC secretion of ECM protein collagen I and IV, laminin and 
fibronectin, which have been shown to have anti-apoptotic effect [159]. Moreover, the rigidity of 
the ECM compresses blood vessels in cancer tissue, which leads to reduce perfusion that 
ultimately impedes the delivery of drugs to cancer cells [145]. However, the lack of significant 
functional perfusion in PDA results not only from a sparse vasculature but also from a profound 
degree of vascular collapse, which are known to contribute to elevated interstitial fluid pressure 
(IFP) [160]. Extremely high IFP was found in autochthonus PDAC, ranging from 75 to as high as 
130 mmHg, which forms a barrier to transcapillary transport [161, 162]. This barrier is an 
obstacle in tumour treatment, as it results in inefficient uptake of therapeutic agents. Lowering the 
tumour IFP by hyaluronidase with a combination use of gemcitabine increased apoptosis in both 
PSCs and PDAC tumour epithelial cell compartments in a KPC mice model [161].  
 
Despite the preponderance of desmoplasia and stromal cells found in pancreatic cancer 
specimens and the fact that fibrosis increases the risk of PDAC, studies of the tumour–stroma 
interactions in this disease have lagged behind. One of the major reasons of poor understanding is 
the lack of suitable models to study these relationships. In vitro co-culturing of cancer cells and 
stromal cells has demonstrated profound effects on cancer cell invasion [163, 164], however, 
most of studies were investigated using two-dimensional cell culture systems, which are vastly 
different from patient situation. Many ECM proteins are also typically absent in such in vitro 
models, which remove an important regulation of PDAC cell behavior [165].  
Creation of cell cultures in three dimension changes the polarity of cells and confers resistance to 
apoptosis [166]. Cells in three-dimensional (3D) culture exhibit similar responses to 
chemotherapy as cells in vivo and could be used as an important tool in pancreatic cancer biology 
[167, 168].  Different techniques can be used to create 3D cultures including suspending cells and 
ECM proteins in gels, attaching cells to 3D scaffolds composed of ECM proteins, growing cells 
on microbeads surrounded by ECM proteins and standard cell culture media, and so on [169]. 
Among current 3D culture techniques, cellular spheroids are a simple 3D model that can be 
generated from a wide range of cell types and form due to the tendency of adherent cells to 
aggregate. Scaffolds are not required for spheroid formation. Spheroids can be readily imaged 
by bright-light, fluorescence, and confocal microscopy. Consequently, 3D culture system using 
cell spheroids has been investigated in cancer researches, such as modelling solid tumour 
growth and metastasis and are also used in a multitude of therapeutic studies, e.g. for high 
throughput screening [170].  
Optimal in vitro models to study pancreatic cancer cell interaction with the adjacent stroma 
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should be 3D and contain appropriate types of ECM proteins and stromal cells. Previously we 
developed a novel 3D PDAC cell culture system using PDAC Panc-1 cells, which displays a 
strongly increased chemoresistant property [168]. However a single cell type cannot accurately 
reflect the complex tumour microenvironment in PDAC. A bigger challenge for an ideal model 
of investigation on tumour–stromal interaction is to develop a 3D cell culture system 
containing the following elements: a pancreatic cancer cell with metastatic feature, activated 
PSCs, ECM containing pre-dominantly collagen and laminin, and the presence of endothelial 
cells, immune cells and neurons, whose presence is also important to the creation and 
regulation of tumour stroma [171]. Attempts to create this type of complex model are underway 
in several laboratories including my group. Therefore, I explored the development of a 
multicellular tumour spheroid model including ductal epithelial cells and PSCs in paper III and 
IV and investigated the sensitivity of our 3D cell culture system of PDAC on anti-cancer drugs.  
1.2.3.2 The hypoxic microenvironment and metabolic reprogramming 
A striking characteristic of the desmoplasia seen in pancreatic cancer is hypovascularity resulting 
in hypoxic conditions that contribute to tumour progression and metastatic potential [172-174]. 
Tumour hypoxia usually occurs at a distance of 100–200 micrometer from blood vessels and cells 
that fail to adapt to O2 and nutrient deprivation undergo cell death by apoptosis and/or necrosis, 
see Figure 8 [175]. Paradoxically, hypoxia can also stimulate tumour development by local 
adaptation that provokes a more aggressive tumour phenotype often in combination with 
chemoresistance. A molecular explanation for adaptation results, for example, from increased 
aerobic glycolysis facilitated by increased expression of glucose transporters and glucose 
metabolizing enzymes, angiogenesis and/ or expression of drug export pumps, e.g. multidrug 
resistance protein 1 (MDR1) [83, 176 and 177].  
 
Figure 8. The characteristics of a hypoxic tumour mass. 
Blood capillaries carry O2 to tissues, but since O2 has a 
diffusion limit, its concentration decreases as the distance 
from capillaries increases. Macroscopic examination of solid 
tumours reveals the presence of expanding tumour cells in 
proximity to capillaries and a central region of necrotic cells. 
This gradient of cell viability parallels that of a decreasing 
gradient of O2, which is accompanied by an increase in HIF-
1α levels, a decrease in the extracellular pH and an increase in 
the resistance to chemo- and radio-therapy. Figure 8 is 
adapted from Brahimi-Horn MC, Chiche J, Pouysségur J: 
Hypoxia and cancer. J Mol Med (Berl) 2007, 85:1301-07. 
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As the key regulator in the adaptations to the hypoxic conditions, HIF-1α expression is observed 
in both pancreatic cancer cells and the surrounding stromal cells [179]. HIF-1 plays a pivotal role 
in hepatic metastasis through its association with the expression of angiogenic factors in PDAC 
patients [180]. Recently, Lu and Kang [181] concluded that each step of the metastasis process 
‘from the initial epithelial-mesenchymal transition to the ultimate organotropic colonization’ can 
potentially be regulated by hypoxia, suggesting a master regulator role of hypoxia and HIFs in 
metastasis. This hypoxia-induced metastatic phenotype may also explain the recent provocative 
findings that antiangiogenic therapy increases metastasis in preclinical models [181-184]. It is 
also likely that the already fibrotic and hypovascular microenvironment of pancreatic cancer is 
one of the reasons for the failure of antiangiogenic therapies in PDAC in the clinical setting [185]. 
Additionally, hypoxia provides a niche for slow-cycling, highly drug-resistant cells, which may 
be identical to the proposed cancer stem cells (CSC) [185, 186]. Thus standard chemotherapy 
agents fail because they are unsuccessful at targeting the cell within the hypoxic 
microenvironment, which might be those that most need to be eliminated [187].  
 
It has been known for a long time that hypoxic cancer cells switch their primary pathway of 
energy production from OXPHOS in mitochondria to glycolysis in the cytoplasm. Otto Warburg 
first observed an anomalous characteristic of cancer cell energy metabolism in 1920’s [188, 189]: 
even in the presence of oxygen, cancer cells can reprogram their glucose metabolism, and thus 
their energy production, by limiting their energy metabolism largely to glycolysis, leading to a 
state that has been termed aerobic glycolysis or Warburg effect. Such reprogramming of energy 
metabolism is seemingly counterintuitive, in that cancer cells must compensate for the ~18-fold 
lower efficiency of ATP production afforded by glycolysis relative to mitochondrial oxidative 
phosphorylation. However the high glycolytic rate allows these cells to balance their energy 
demands and supply the anabolic precursors for de novo nucleotide and lipid synthesis [190]. 
This strategy is considered to provide a growth advantage for the tumour cells, though it renders 
cells highly dependent on substrate availability for survival [191]. Another important feature of 
this hypoxic microenvironment in tumour is acidosis, which is a consequence of increased 
glycolysis leading to production of lactate and of defective vascular evacuation of metabolic 
lactic acid and CO2 [192]. It has been reported the acidic environment has a strong impact on the 
activity of the p-glycoprotein drug transporter responsible for multidrug resistance [193].  
 
Several mechanisms for the enhanced glycolysis in tumour cells have been investigated and 
suggested as increased expression of the glycolytic enzymes and glucose transporters or 
decreased expression of mitochondrial oxidative enzymes and transporters [194]. This switch has 
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now been revealed to implicate, at least in part, [195] HIF-1 induced glucose capture, glycolytic 
flux and inhibition of OXPHOS. HIF-1α enhancement promotes the expression of glucose 
transporter (GLUT), hexokinase (HK), phosphofructokinase type-1 and -2, aldolase, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), phosphoglycerate kinase, enolase, 
pyruvate kinase and lactate dehydrogenase (LDH) [196, 197], which leads to a stimulation of the 
glycolytic flux. HIF-1α also favors the glycolytic flux by repressing OXPHOS through induction 
the expression of pyruvate dehydrogenase kinase-1 (PDK-1), an inhibitor of pyruvate 
dehydrogenase, the enzyme that drives pyruvate into the TCA cycle for mitochondrial respiration 
[198, 199]. As described above, oncogenic events have been linked to stabilization of HIF-1α in 
the presence of adequate O2, such as RAS-MAPK and PI-3K/AKT signaling [200]. Moreover, 
mutations of the TCA cycle tumour suppressors, succinate dehydrogenase and fumarate 
hydratase can also lead to stabilization of HIF-1α. In particular, prolyl hydroxylation of HIF-1α 
requires α-ketoglutarate as a substrate, which is converted to succinate, thereby inhibiting the 
degradation of HIF-1α [200]. Furthermore, intracellular ROS levels paradoxically increase under 
hypoxia where mitochondria appear to be their main source of production [201]. Studies have 
shown that these mitochondria-derived ROS are both necessary and sufficient to stabilize and 
activate HIF-1 [202, 203] most probably via modulation of PHD activity [204]. This signaling 
effect of ROS in activation of HIF-1 pathways thereby proposes a possible feedback loop, which 
would attenuate the toxic burst of hypoxic ROS [205]. 
 
Apart from microenvironment factors described above, other potential HIF regulators have been 
identified, such as extracellular glucose. Glucose is also delivered by the blood circulation and 
diffuses into tissues for cell capture, like oxygen. A decrease in the amount of glucose provided 
to hypoxic cells was shown to result in a decrease in the level of HIF-1α [205] or to have no 
effect [206]. The explanation for this difference may lie in either the different cell lines or the 
level of hypoxia (0.1 or 1.0% O2). But HIF-1α expression is increased in malignant and non-
malignant cells with high extracellular glucose [206, 207]. However, it is still uncertain whether 
excess glucose stimulates HIF-1 expression in pancreatic cancer and if glucose-induced HIF-1α is 
correlated with tumour aggressiveness. Therefore, I investigated the effect of high glucose on 
HIF-1 expression in PDAC cells in paper II with regard to metastasis.  
 
In addition to hypoxia induced HIF-1 expression, oncogenic activation or loss of tumour 
suppressors is widely involved in metabolic alterations of human cancers, which independently, 
or cooperatively with hypoxic adaptive responses contributes to tumourigenesis. For example, K-
Ras oncogenes can enhance glucose transport and glycolysis in transformed cells [10]. Most 
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glycolytic enzyme genes and glucose transporter genes are directly or indirectly induced by c-
Myc transcription factor [11]. Akt, independent of HIF-1, can also activate glycolysis through 
induction of glucose transporters and HK-II [11]. The loss of p53 leads to derepression of the 
transcription of the GLUT1 and GLUT4 and loss of glycolysis repression [12]. Perhaps one 
function of oncogenic pathways is to drive cell-autonomous nutrient uptake and program 
proliferative metabolism, whereas one function of tumour suppressor pathways is to prevent 
nutrient utilization for anabolic processes. 
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2 AIMS 
The overall objective of this thesis was to investigate the roles of HIF-1α in endocrine β-cells of 
pancreatic islets and in exocrine ductal epithelial cells as well as their surrounding stromal cells 
of pancreatic ductal adenocarcinoma.   
 
Specific aims were:  
 
 To investigate mechanisms of effects of exendin-4 on islet function and viability in a 
rodent islet transplantation model with special focus on HIF-1α expression. (Paper I) 
 To investigate relationship of the role of excess glucose on glucose reprogramming and 
cell migration in human PDAC cells with respect to HIF-1α expression. (Paper II) 
 To develop a high-throughput 3D model of human PDAC cells, and to further explore 
mechanisms underlying the transition from 2D to 3D that might be responsible for 
chemoresistance, including hypoxia-inducible factor-1 pathway. (Paper III) 
 To improve the development of a 3D model of human PDAC cells and PSC cells, and 
to evaluate its potential properties similar to a stromal and hypoxic PDAC in vivo. 
(Paper IV) 
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3 MATERIALS AND METHODS 
3.1 MATERIALS AND MODELS 
3.1.1 Animals (Paper I) 
The animal experiments were approved by the local Animal Ethics Committee (S19-07, S177-06 
and S9-05). All animals were maintained in accordance with the requirements of the Animal 
Welfare Act and the National Institutes of Health guidelines for the care and use of laboratory 
animals.  
 
Male Sprague Dawley rats (weighting 300g) were used as islet donors, whereas male inbred 
athymic mice (nu/nu Black 6, weighing 25 g) served as recipients. These immunoincompetent 
nude mice cannot reject cellular grafts, thus the survival of the transplanted islets is not 
influenced by any rejection reaction. Diabetes was induced at mice by the injection of 
streptozotocin (250 mg/kg body weight) into the penile vein under inhalation anesthesia using 
Enflurane. Mice were considered diabetic if its non-fasting blood glucose level exceeded 20 
mmol/l (>360 mg/dl) for 2 consecutive days and used as transplant recipients. During the 
experiments, the animals had free access to tap water and pelleted food. Prior to the glucose 
tolerance tests, the animals were fasted overnight.  
 
3.1.2 Cell lines and incubation (Paper I-IV) 
INS-1E cells were a kind gift from Dr. P. Maechler [208]. Cells were cultured in RPMI-1640 
medium supplemented with 10% (vol/vol) fetal bovine serum (FBS), 10 mM HEPES, 100 U/ml 
penicillin, and 100 μg/ml streptomycin, 1 mM sodium pyruvate, and 50 μM β-mercaptoethanol 
under standard conditions (37°C, 95% air and 5% CO2). Due to the variable hypoxia within 
islets, the rat insulin producing cells were used to evaluate the effects of exendin-4 on energy 
production. During incubation with various exendin-4 treatments, cells were first cultured in 
serum-free RPMI-1640 medium under standard conditions for 20 hours. Then they were 
changed into new serum-free medium with various exendin-4 concentrations and incubated in 
normoxia (95% air and 5% CO2) or hypoxia (1% O2, 5% CO2 and 94% N2) for 2 hours. The 
concentrations of O2 and CO2 were monitored using a gas meter. Two hours incubation with 
hypoxia was determined according to our preliminary test (data were not shown). (Paper I) 
Wild-type MiaPaCa2 human PDAC cells (wt-MiaPaCa2) and a MiaPaCa2 sub-line (namely si-
MiaPaCa2) were prepared as described in previous study of our group, and the latter lacked HIF-
1α [209]. Human PDAC cell lines BxPC-3 and Panc-1 [210] were bought from the European 
  32 
Collection of Cell Cultures. All cells were cultured under standard conditions in Dulbecco’s 
modified Eagle’s media (DMEM) with 5.6 mM glucose containing 10% FBS. In order to 
evaluate the effect of excess glucose in PDAC cells, cells were maintained with a physiological 
blood glucose level. When cells reached to 80% confluent, experimental incubation was set up, 
using DMEM (Invitrogen, 11966, originally glucose-free) or KH buffers supplemented with 
known amounts of glucose. Cells were incubated in normoxia (95% air and 5% CO2) or hypoxia 
(1% O2, 5% CO2 and 94% N2). The incubation time of hypoxic treatment was determined 
according to pervious publication of members of our group [209]. During hypoxic incubation, a 
gas meter (Dansensor) was used to monitor the O2 and CO2 concentrations (Paper II)  
 
Human PDAC cell lines AsPC-1, BxPC-3, Capan-1, Paca44 and Panc-1 [210, 211] as well as a 
normal human pancreatic ductal epithelial cell line HPDE were obtained from the American 
Type Tissue Collection. The PSC cell line derived from patients with chronic pancreatitis and 
subsequently transformed [212]. KPC cells were established from a mouse PDAC model, 
carrying pancreas-specific Kras and p53 mutations (Kras
LSL-G12D/+
;Trp53
LSL-R172H/+
;p48-Cre; 
hence KPC) [213].  Cells were cultured under standard culture conditions in DMEM/F12 or 
phenol red-free DMEM/F12 medium containing 10% fetal calf serum. In order to train PSC to 
grow as 3D, they were cultured on the 1% agarose gel (Invitrogen, life technology) for at least 
three months as conditioned PSCs (PSC-c), and then they were seeded back to cell culture flask 
at one day before preparing spheroids. (Paper III and IV) 
 
3.1.3 Rat islet preparation and culture (Paper I) 
Rat pancreatic islets were isolated using collagenase digestion and discontinuous density 
gradient purification. In inhalation-anesthetized rats, pre-cold collagenase P solution (0.7mg/ml 
and 20ml/rat, Roche Diagnostics GmBh) was injected into the pancreas via the common bile 
duct. Rats were euthanized by heart exsanguinations after removal of the pancreas. Enzymatic 
digestion of pancreas was carried out at 37°C. Then the density gradient centrifugation was 
performed at 4°C, where pelleted digested tissue was resuspended in Histopaque-1119 and 
culture medium RPMI 1640 was carefully added to form a sharp interface. After centrifugation 
islets were collected from the interface. Islet purity was about 90%, as estimated 
semiquantitatively under microscope. 
Islets were floating cultured in culture medium RPMI 1640 with exendin-4 (0 or 0.1 nM) under 
standard conditions for 20 hours, supplemented with 10% FBS, 2 mmol/l L-glutamine, 50 U/ml 
penicillin and 50 mg/ml streptomycin. At the following day, islets were handpicked and used 
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for transplantation.  
3.1.4 The TheraCyteTM device and macroencapsulation (Paper I) 
The TheraCyte
TM
 device with a volume of 4.5 μl (see Figure 9) was used for islet macro-
encapsulation in this thesis. In order to improve the procedure of macroencapsulation in islet 
transplantation and investigate the effects of exendin-4 on macroencapsulated islets, a 
suboptimal number of islets (500) were cultured for 20 hours in either the presence or absence 
of exendin-4 (0.1 nM). Then islets were handpicked and 
loaded into the device using a neonatal venflon cannula 
attached to a Hamilton syringe. After loading, the port 
was sealed with glue to avoid islet leakage and growth of 
host tissue into the device lumen.  
Figure 9. The TheraCyte
TM 
device with a lumen volume of 4.5 μl was 
used in Paper I.  
3.1.5 Islet transplantation model and recipient management (Paper I) 
Renal sub-capsular islet transplantation  
Thirty rat islets cultured for 20 hours were handpicked and washed once with HBSS. Then free 
islets were transplanted beneath the kidney capsule of mice with inhalation anaesthesia 
(Enflurane) as previously described [121]. The kidney capsule is already considered as a 
successful islet transplantation site in experimental islet transplantation. In our model, the 
diabetic athymic mice were repeatedly cured by 50 rat islets but not by 30 islets, as shown in a 
previous study [121]. To mimic the clinical situation, we used a marginal mass of 30 free islets in 
this study.  
 
Encapsulated islet transplantation 
Macroencapsulated islets were implanted subcutaneously on the back of inhalation-anaesthetised 
mice. As fresh implantation, islets were inserted in vitro into the device’s lumen just before 
implantation.  
After transplantation, non-fasting blood glucose levels and weights of the animals were 
measured daily during the first week. Measurements were always done prior to injecting the 
study drug or insulin. Thereafter, mice with blood glucose levels below 10 mM for 2 
consecutive days were assessed twice a week. The mice with hyperglycemia (≥ 11 mM) were 
checked daily. The mice with blood glucose levels above 20 mM received a mixture of short- 
and long-acting human recombinant insulin subcutaneously as previously described [121]. 
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Animals that could not maintain their general condition on insulin treatment due to severe 
diabetes were sacrificed earlier, in accord with regulations pertaining to animal welfare.  
An intraperitoneal glucose tolerance test (IPGTT) was performed in all cured mice after 4 
weeks. Before the IPGTT, mice were fasted for at least 6 hours. Glucose (20%) was injected i.p. 
(10 l/g) and the blood glucose level determined before injection and then at 5, 10, 15, 20, 30, 45, 
60, 90 and 120 minutes after the injection. Healthy mice were used as normal controls and 
tested simultaneously. After IPGTT, graftectomy was done to rule out a recurrence of native 
pancreatic function in all cured and partially cured animals. The mice were then sacrificed by 
cervical dislocation.  
3.1.6 Three-dimensional (3D) cell culture model (Paper III and IV) 
In order to create an easy technique for high-throughput screening application, we used a 
crowding agent methylcellulose, a cellulose-derived inert compound, to help cells to aggregate 
and form spheroids. Moreover, exogenous ECM components were not required in our method 
avoiding its possible effects on cell signaling [169]. Cells (2500 cells/well for mono-spheroids; 
1750 cells/well PDAC cells mixed with 750 cells/well PSC-c for hetero-spheroids) were seeded 
onto round bottom non-tissue culture treated 96 well-plates in 100 μl DMEM-F12 medium, 
containing 10% FCS and supplemented with 0.24% methylcellulose. Spheroids were grown 
under standard culture conditions and harvested at different time points for RNA, protein 
isolation and drug testing. In Paper III, growth kinetics of mono-spheroid was performed by 
cell counting after trypsinization. In Paper IV, the diameter of different spheroids referred as 
the growth curve was evaluated using a light microscope by the same investigator (P. L.). A 
general image analysis of cell spheroids was performed a fluorescent microscope (Axiophot, 
Zeiss) equipped with a CCD camera (AxioCam MRc, Zeiss) and imported into image analyzer 
software (AxioVision Rel. 4.6, Zeiss). 
3.2 METHODS  
3.2.1 Quantitative real-time PCR (qPCR) (Paper I-IV) 
Total RNA from rat islets or cultured cells as well as spheroids was extracted using the RNeasy 
or the miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instruction. RNA integrity and concentration were analyzed using agarose gel electrophoresis 
and Nanodrop
®
 Spectrophotometer ND-100 (Saveen& Werner AB, Linhamn, Sweden). 
In paper I, real-time PCR was performed by the ABI Prism 7000 instrument using SYBR
® 
Green 
PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and predesigned primer sets 
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(QuantiTect
®
 primers, Qiagen) for rat Hif-1α, pancreatic and duodenal homeobox-1 (Pdx-1), B-
cell lymphoma 2 (Bcl2), and 18S ribosomal RNA. Data were analyzed by ABI Prism 7000 SDS 
software. In paper II, HIF-1α mRNA was determined in a TagMan duplex real-time PCR, using 
18S rRNA as an endogenous control. In Paper III and IV, we also used SYBR green (Fermentas, 
Thermo Scientific Life Science Research) binding to amplified cDNA for target genes and 
ribosomal protein L13 were used as the endogenous control genes in human PDAC cells. Then 
qPCR was performed in the C1000
TM
 Thermal Cycler equipped with CFX96
TM
 Real-time PCR 
System (BIO-RAD). Further detailed information regarding oligonucleotide primers is described 
in original papers. The CT method was used for result calculation in all included papers. 
 
3.2.2 Western blotting (Paper I-IV) 
For protein extraction, the nuclear and cytosolic proteins were sequentially extracted from either 
isolated islets or cultured cells according to the protocol of Schreiber et al [214], in paper I and II. 
In paper III, IV and some experiments of paper II, commercial cell lysis buffers such as RIPA 
and M-PER
® 
were also used to prepare whole-cell proteins. After separated by SDS-PAGE gel 
electrophoresis, the proteins were then transferred to Immobilon-P membrane (Millipore) where 
they were exposed to a primary antibody specific to the target protein. Thereafter a HRP (horse 
radish peroxidase)-conjugated secondary antibody was applied. The HPR cleaves a 
chemiluminescent substance, and the reaction product produces bioluminescence that can be 
detected by photographic film or CCD camera. The image was analyzed by densitometry using 
ImageJ software. The antibodies used in this thesis are described in original papers.  
 
3.2.3 Insulin measurement (Paper I) 
The total amount of insulin in renal subcapsular islet grafts was detected in the whole graft-
bearing kidneys. Both kidneys were removed immediately after the mice were sacrificed by 
cervical dislocation and were quickly frozen in liquid nitrogen and kept at −80°C until use. 
Insulin was extracted from kidneys by means of acid ethanol. The insulin concentrations in 
homogenates were then determined using ELISA (Mercodia). The Merocodia Insulin ELISA is 
a two-site enzyme immunoassay utilizing the direct sandwich technique with two monoclonal 
antibodies directed against separate antigenic determinants of the insulin molecule.  
3.2.4 Intracellular ATP assay (Paper I and II) 
For the measurement of ATP, serum-free medium or Krebs-Henseleit (KH) buffer with study 
objects were used for cell incubation. In paper I, ATP assays were performed on cells after the 
hypoxic incubation using an ATP bioluminescent somatic cell assay kit. Since the bioluminescent 
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kits require specialized luminescence instrumentation and utilize luciferase that can be difficult to 
maintain in active form. In paper II, ATP content in cells was determined using a newly 
developed ATP colorimetric assay kit from BioVison. This kit is designed to be a robust, simple 
method that utilizes the phosphorylation of glycerol to generate a product that is easily quantified 
by colorimetric method. Cellular proteins were determined using a BCA assay kit. Original ATP 
values were normalized by protein contents. 
 
3.2.5 Measurement of glucose consumption and lactate content (Paper II and III) 
In paper II, glucose consumption and lactate production were determined in removed buffers 
after cell incubation using a biochemical analyzer. Before incubation, cell culture medium was 
changed to KH buffers with different glucose concentrations. Cellular proteins were determined 
using a BCA assay kit. Glucose consumption was calculated by subtracting measured glucose 
from original glucose concentrations. KH buffer does not contain lactate, so lactate contents in 
used buffers indicated lactate-production rates in cells (hence glycolysis levels in the cells). The 
original data of glucose consumption and lactate production were normalized with protein 
contents. 
Since culture media were not changed during experiments, lactate contents in removed media 
were determined using a biochemical analyzer at the end-point of the experiments, considered 
as lactate accumulation. Concentration of lactate was calculated by subtracting measured 
lactate from original glucose concentrations in the cell-free medium. And it was normalized 
with protein contents as described above. 
3.2.6 ROS measurement (Paper II) 
Intracellular ROS levels were detected in vitro using a fluorescent probe CM-H2DCFDA 
according to the manufacturer’s recommendations. CM-H2DCFDA is a chloromethyl derivative 
of H2DCFDA, useful as an indicator for ROS in cells. The probe becomes fluorescent after 
oxidation by H2O2, OH

, ROO
 
and ONOO
-
. At the end of the incubation period with different 
glucose concentrations and O2 tensions, wt-MiaPaCa2 cells were loaded with 5 μM ROS probe 
in pre-warmed phosphate buffer, incubated for 15 min at 37°C. After washing the cells twice 
with PBS, fluorescence was detected at 480 nm (excitation) and 525 nm (emission) using a 
flow cytometer. 
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3.2.7 Histological Studies (Paper I, III and IV) 
Hematoxylin and eosin (H&E) staining 
For visualization of cells in spheroids, formalin-fixed spheroids were embedded in paraffin, and 
sectioned into 7 μm thick sections. They were then stained with H&E and observed in a light 
microscope. (Paper III and IV) 
In paper I, H&E staining was performed on sections (5 μm thick) of macroencapsulated islet 
grafts with a distance of 74 μm, prior to analyses of volume densities and vascular profiles. 
Volume densities (i.e., fractional volumes and absolute volumes) and vascular profiles were 
evaluated by morphometry. Procedures in detail are described in original papers. All 
examinations were performed blindly on coded specimens by the same investigator (M.K.). The 
micrographs were counted twice and the intraobservation variability was found to be less than 
10%. 
 
Electron microscopy analysis 
In order to better investigate the cellular morphology in detail, especially the cell-cell contact in 
the spheroids, the electron microscopy analysis was performed in studies of paper III. Spheroids 
were fixed in phosphate buffer (pH7.4) containing 4% glutaraldehyde and 1% paraformaldehyde, 
and subsequently embedded and processed. Imaging was performed on a Tecnai 12 Spirit Bio 
TWIN transmission electron microscope at the Central Electron Microscopy Unit of Karolinska 
Institutet. 
 
Immunofluorescent staining 
In studies of paper I, we used direct and indirect immunofluorescent staining methods to identify 
insulin and glucagon on the same macroencapsulated islet grafts, respectively. Nuclei were 
stained with DAPI. The slides were examined using an Olympus fluorescent microscope and the 
localization and number of specific endocrine cells were evaluated using the Cell^F Imaging 
Software. For paper III and IV, indirect immunofluorescent staining method was performed to 
stain ECM proteins and other specific proteins expressed either in epithelial cells or PSCs. The 
antibodies used in this thesis are described in original papers. DAPI was used for nuclei staining. 
The slides were examined using a Zeiss fluorescent microscope.  
 
3.2.8 Cell migration assay (Paper II) 
In paper II, we used a Boyden chamber with a porous membrane (pore diameter=12 μm) coated 
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with fibronectin to analyze the effect of high glucose on cell migration in hypoxic MiaPaCa2 
cells. IGF-I (50ng/ml) was used in the lower compartment of chamber as an additional 
chemotactic agent. After a 16-h normoxic or hypoxic incubation, the membrane was removed. 
Cells that migrated to the opposite side of the membrane were counted under a light 
microscope. 
3.2.9 Cell viability assay for drug test (Paper III) 
Most routinely used cell viability assays (i.e. trypan blue dye exclusion assay and MTT assay) 
are designed for monolayer cultured cells or a single cell suspension, they could not be easily 
adapted for application in 3D cultures. In order to estimate the efficacy in spheroid versus 
monolayer cells of different compounds, a slightly modified acid phosphatase (APH) assay 
[215] was performed in different cells, including 3 human cancer cell line, one human non-
tumour cell line and one rat cell line, at the end of the exposure period in studies of paper III. 
APH assay, which is based on quantification of cytosolic acid phosphatase activity, was 
reported as most suitable tool to determine cell viability in complex 3D cultured cells for the 
anti-cancer drug screening [215]. To validate the APH assay on our 3D culture system, a 
regrowth assay and the secondary APH assay were performed after drug testing.  
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4 RESULTS AND DISCUSSION 
4.1 Paper I: 
Exendin-4 increases the expression of hypoxia-inducible factor-1α in rat islets and 
preserves the endocrine cell volume of both free and macroencapsulated islet grafts. 
In a previous study, we demonstrated that a combination of islet preculture and recipient 
treatment with exendin-4 improves the metabolic outcome of a suboptimal number of rat 
islets transplanted to diabetic athymic mice [121]. However, that study did not compare the 
individual impact of islet preculture or recipient treatment on graft outcome. In addition, the 
effects of exendin-4 on macroencapsulated islets, which are another useful islet 
transplantation model established in our group [138], have not yet been studied.  
 
In paper I we therefore compared the individual effect of islet preculture and recipient 
treatment on free islet graft outcome, using three different treatment protocols of exendin-4 
(see Table 1). We found that islet preculture with exendin-4 followed by a short-term 
recipient treatment improved the metabolic outcome when a marginal mass of islet graft was 
transplanted under the kidney capsule. Similar effects of exendin-4 treatment were observed 
when islets were transplanted in an immunoprotective device subcutaneously. 
 
Table 1. Ex-4 treatment protocols for mice transplanted with 30 free islets under the kidney capsule. 
Groups Ex-4 in islet culture medium Mouse treatment with Ex-4
a 
1 - - 
2 + - 
3 - + 
4 + + 
a 
From day 0 to 7, recipient mice were treated (i.p.) with 100 ng exendin-4 (+) or with vehicle only(-).  
 
Our finding from in vivo experiments was further confirmed by the total insulin content data 
of free islet transplantation and histological analysis of the macroencapsulated islet graft. 
Significantly greater insulin content was found in the group given combined exendin-4 
treatment. As the only insulin storage cells in pancreas, the higher introcellular insulin 
content indicates the better-maintained β-cell mass in the presence of exendin-4 and suggests 
that this effect is related to improved β-cell survival. Moreover, the exendin-4-treated group 
had significantly larger endocrine volume, less graft necrosis, and more blood vessels around 
the capsule in macroencapsulated grafts. The majority of endocrine cells were positive for 
insulin, while only a few cells were glucagon positive. 
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β 
 
We further investigated the protective effects of HIF-1 on islet graft with exendin-4 
treatment. It has been known that transplanted islets can be damaged by severe inflammation 
and hypoxia before the vascularization in the grafts is established. However, a number of 
genes are also up-regulated for better cell survival followed by overexpression of HIF-1 [3, 
81 and 84]. Our western blotting confirmed the existence of stabilized HIF-1α protein in the 
isolated rat islets. Markedly, expression of HIF-1α protein is increased by extendin-4 in a 
dose-depended manner after an overnight culture. On the contrary, expression of the pro-
apoptotic enzyme caspase-3 was attenuated in the islets (see Figure 10). Furthermore, the 
anti-apoptotic gene Bcl2 and a β-cell differentiation factor, Pdx-1, as well as HIF-1α were 
up-regulated on the mRNA expression level in the exendin-4-treated islets (see Figure 11). 
These findings indicate that HIF-1 up-regulation by exendin-4, in concentrations used here, 
confers a protective effect in islets. In addition, exendin-4-treated INS-1E cells produced 
more ATP than control cells under hypoxic conditions, indicating that exendin-4 increases 
glycolysis in islet graft and thereby improves its energy production.  
 
 
  
Figure 10. Western blot analyses assessing hypoxia inducible factor (HIF)-1α (A) and active caspase-3 (B) 
expression levels with/without exendin-4 treatment. The upper part of each panel shows specific bands of 
indicated proteins, whereas the lower part shows the fold change of target protein level/loading control protein 
level compared to the respective control samples (n = 6 in each group). **p < 0.01, *p < 0.05. 
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Figure 11. Real-time PCR analysis of Hif-
1α (A), pancreatic and duodenal 
homeobox 1 (Pdx-1) (B), and B cell 
lymphoma 2 (Bcl2) (C) gene transcripts in 
isolated islets with/without exendin-4 
treatment. Fold changes of target gene 
mRNA level/the endogenous control 
mRNA level are com- pared to the 
respective control samples (n = 3–6). *p < 
0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although our in vitro data showed that a 20-h incubation of islets with exendin-4 improved 
islet viability, we observed that only the preculture of islets with exendin-4 (without recipient 
treatment) did not improve metabolic control after islet transplantation in the in vivo study. 
Combined with our previous finding that a short-term recipient treatment with exendin-4 
improved metabolic control after islet transplantation when evaluated a few days after the 
discontinuation of the treatment [121], we propose that the anti-apoptotic effects of exendin-
4 initiated in vitro may be complemented by a direct effect of exendin-4 on transplanted 
grafts as well as indirect effects of exendin-4 on the recipient mice such as glucose-
dependent stimulation of insulin secretion [124] and the suppression of glucagon secretion 
[125]. 
 
Our data from the rodent models indicate that a shorter initial exendin-4 treatment may be of 
value to preserve islet graft mass. This study has indicated for the first time that the 
(A)
Exendin-4 (nM):           0                       0.1                     10
*
(B)
*
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*
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*
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protective effects of the GLP-1 receptor agonist exendin-4 may be mediated via the HIF-1 
pathway. 
 
4.2 Paper II: 
Excess glucose induces hypoxia-inducible factor-1α in pancreatic cancer cells and 
stimulates glucose metabolism and cell migration. 
Although aerobic glycolysis has now been generally accepted as a metabolic hallmark of 
cancer, the underlying mechanisms are still unclear. One compelling idea to explain the 
Warburg effect is that the altered metabolism of cancer cells confers a selective advantage 
for survival and proliferation in the unique tumour microenvironment. As the early tumour 
expands, it outgrows the diffusion limits of its local blood supply, leading to hypoxia and 
stabilization of HIF-1α [175, 178]. In addition, HIF-1α can be affected by other 
environmental characteristics, such as nutrients, pH and ECM [216]. Increased extracellular 
glucose has been reported to regulate HIF-1α expression in benign cells [207, 217]. Since 
pancreatic cancer is frequently associated with diabetes [218], it offers cancer cells a 
microenvironment with high glucose concentration. We hypothesized that hyperglycemia in 
pancreatic cancer patients may facilitate cancer cells to reprogram glucose metabolism via 
HIF-1α and thereby increase cancer cell aggressiveness. In order to investigate whether the 
excess glucose-induced HIF-1α stimulates aerobic glycolysis in PDAC cells, a MiaPaCa2 
subline (namely si-MiapaCa2) was used in paper II, which stably expresses HIF-1α-specific 
small interfering RNA. 
 
We found that the expression of hypoxia-induced HIF-1α was increased by extracellular 
glucose stimulation (5.6-22.2 mM) in wt-MiaPaCa2 human pancreatic cancer cells (see 
Figure 12). Furthermore, high glucose not only stabilized HIF-1α proteins, but also up-
regulated HIF-1α transcription resulting in enhanced HIF-1α mRNA level in both normoxia 
and hypoxia. Whereas HIF-1α-production rates might be still slower than HIF-1α-
degradation rate at protein level in the normoxic cells, HIF-1α protein was expressed in 
MiaPaCa2 cells under hypoxia rather than normoxia. Furthermore, the excess glucose-
induced HIF-1α-production requires PI-3K activity in MiaPaCa2 cells. We found that excess 
glucose stimulated the expression of PI-3K (p85 subunit) in a dose-dependent manner in 
hypoxia and glucose induced HIF-1α was attenuated by PI-3K inhibitor in hypoxic wt-
MiaPaCa2 cells.  
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Figure 12. Wt-MiaPaCa2 (upper) and si-MiaPaCa2 
(below) pancreatic cancer cells were incubated with 
different amount of glucose in hypoxia or normoxia 
for six hours. HIF-1α was determined by western 
blotting, using GAPDH and Topo1 as loading 
control.                                                                                             
   
 
 
 
Clearly, si-MiapaCa2 cells were devoid of HIF-1α in both normoxia and hypoxia. And in 
hypoxic si-MiapaCa2 cells, HIF-1α expression was not up-regulated upon excess glucose 
stimulation (see Figure 12). We first investigated the expression of HK-II in wt- and si-
MiaPaCa2 cells exposed to different amounts of glucose in hypoxia or normoxia, which is 
one of the key glycolytic enzymes in glycolysis. Although the induction of HK-II expression 
was up-regulated by increased glucose levels in all examined cell types, excess extracellular 
glucose induced greater HK-II expression in wt-MiaPaCa2 cells than in si-MiaPaCa2 cells In 
hypoxia. Therefore glucose might stimulate HK-II expression through not only HIF-1α but 
also other non-hypoxic factors. To further assess glucose metabolisms in MiaPaCa2 cells 
with excess extracellular glucose, we determined glucose consumption, lactate production 
and intracellular ATP in wt- and si-MiaPaCa2 cells in normoxia and hypoxia after a 6-hour-
incubation with different amounts of glucose. KH buffers with different amounts of glucose 
were used as culturing media during experiment to avoid interference from other 
components in culture media. For example, it has been recently shown that hypoxic cancer 
cells also use glutamine as a carbon fuel source for survival [219]. When glucose becomes 
the sole carbon fuel source in studied cells, glucose consumption represents cellular glucose 
uptake in glycolysis and lactate production in culture media is another index of glycolysis 
levels. A practical ratio between these two parameters compared to an ideal value, which 
happened in glycolysis, was further investigated to show the levels of glycolysis relative to 
other glucose metabolisms. However we found hypoxia-increased glycolysis in MiaPaCa2 
cells is independent of extracellular glucose, though HIF-1α expression improved ATP 
production. As described above, other intracellular regulators of glucose metabolisms, such 
as Akt, c-Myc and TP53, may regulate the hypoxia-induced glycolysis [10, 11]. As various 
mechanisms of aerobic glycolysis modulation were reported in different cancer cell types, 
we further investigated the mitochondrial activities in MiaPaCa2 cells with increased glucose 
stimulation in hypoxia and normoxia. The glucose-induced HIF-1α stimulated both PDK-1 
  44 
expression and ROS reduction in MiaPaCa2 cells, which indicate a less mitochondrial 
activities associated with glucose-induced HIF-1α. In addition, cell migration in MiaPaCa2 
cells was stimulated by glucose via both HIF-1α dependent and independent mechanism.  
 
We demonstrated excess glucose stimulates HIF-1α expression, increases ATP contents and 
stimulates migration in MiaPaCa2 PDAC cells, however, extracellular glucose and hypoxia 
may not regulate glucose metabolisms and cell migration depended on HIF-1α alone. It is 
possible that PDAC cells appear to use glycolytic metabolism before exposure to hypoxic 
conditions. For example, leukemic cells are highly glycolytic [220], yet these cells reside 
within the bloodstream at higher oxygen tensions than cells in most normal tissues. More 
recently, a study using a Pdx1-Cre;Ink4a/Arffl/fl;LSL-KrasG12D mouse model of 
pancreatic cancer showed hypoxia increases the “glycolytic” switch of pancreatic cancer 
cells from OXPHOS to  lactate production and increased lactate efflux from hypoxic cancer 
cells favors the growth of neighboring normoxic cancer cells. Their study partly confirmed 
our hypothesis whereas HIF-1α was not investigated in their study. Therefore, more studies 
are required to clarify the effects of glucose and hypoxia on pancreatic cancer cells and a 
better pancreatic cancer experimental model should be considered to study glucose 
metabolism of pancreatic cancer.  
4.3 Paper III: 
3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype 
offering a better model for drug testing.  
Although improvements in cancer treatment modalities have been achieved, current cure 
rates are not satisfactory for many forms of advanced cancer diseases [221], such as PDAC. 
There is a large medical need for novel, efficient anti-cancer agents. Consequently, an in 
vitro model as a more predictive platform is strongly required for drug screening.  
 
Most of published 3D culture studies in PDAC used biomaterial scaffolds (hydrogels or 3D 
porous scaffolds) to replicate the natural extracellular matrix required for native cell 
function. To avoid the existence of exogenous ECM components in our 3D culture system, 
we designed a model as spheroids of PDAC cells by adding the crowding agent 
methylcellulose in suspension culture. A single cell spheroid per well can be easily and 
reproducibly formed using our technique and thus be used for high-throughput drug 
screening. We used 2500 cells/well in U-bottom 96-well plates, which allow the diameter of 
spheroid below 500 μm during the 7-day growth period. Different PDAC cell lines were 
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tested, including Panc-1, MiaPaCa2, BXPC3 and ASPC-1, and showed different ability to 
form spheroids. Panc-1, carrying both KRAS and p53 mutation, was then selected for further 
testing in paper III. Cellular morphological analysis revealed that cells were homogeneously 
distributed in spheroid without big central necrosis and their spherical structures contained a 
hollow perceptible lumen indicating a spatial organization in 3D similar to that in vivo 
tumour. Moreover, tight junctions were identified between adjacent cells in Panc-1 cell 
spheroids. This is in agreement with a higher expression of E-cadherin was observed in 3D 
cultured Panc-1 cells rather than 2D cultured cells. Panc-1 cells formed relatively compact 
and round spheroids (see Figure 13), but cell proliferation was not increased as much as in 
2D cultured cells. However cell viability was similar in both 2D and 3D cultured cells during 
7-day culture, approximately 90%.   
 
 
Figure 13. Development of a single representative Panc-1 spheroid, photographed from day 2 to day 8 by 
counting with the Boyden chamber the cell number of trypsinized spheroids and taking pictures of spheroids at 
fixed time points. Scale bar represents 500 μm. 
 
Based on our current knowledge regarding chemoresistance in PDAC [222-225], we 
investigated glucose metabolism and expression of genes related to stroma, hypoxia, as well 
as chemoresistance in 2D and 3D cultured PDAC cells and compared cellular response to 
anti-cancer drugs using the same cell setting. Firstly, we found that endogenous ECM 
components were stimulated when cultured cells underwent 2D-to-3D transition. For 
example, the mRNA expression of FN, COL6A1 and COL1A was higher in 3D during the 
sphere formation (contact making) as well as compaction phase and the protein expression of 
collagen I and fibronectin I was observed from one day-7-spheroid section by 
immunohistochemistry. In addition, the proteoglycan lumican and a new stromal marker 
SNED1 (sushi, nidogen and EGF-like domains 1) were also up-regulated in our 3D cultured 
Panc-1 cells, which display associated chemoresistant property. Furthermore, miRNA-146a 
was strongly up-regulated when Panc-1 cells were grown in 3D, indicating the forced 
immobilization of cancer cells in the spheroid. Secondly, glycolysis was stimulated in 
association with an increased hypoxia-inducible gene expression. As the end product of 
glycolysis, we compared lactate accumulation in 2D and 3D cultured Panc-1 after a 10-day-
culture. Lactate accumulation increased significantly more in 3D than 2D cell culture 
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medium after 5 days, indicating a metabolic switch to increased glycolysis in 3D. Moreover, 
HIF-1α was stabilized and expressed in both 2D and 3D cultured Panc-1 cells, whereas 3D 
cultured cells exhibited a highest content particularity at day 4. Our result suggests both 
hypoxic and non-hypoxic factors modulate the expression of HIF-1α in Panc-1 cells. 
Following HIF-1α, the expression of genes of glucose transporters, glycolytic enzymes, 
growth factors and proliferation was all up-regulated in 3D cultured cells, including GLUT1 
and 12, HK-II, LDHA, VEGFA, PDGFB and PTGS2. Thirdly, chemoresistance-related 
genes were up-regulated in 3D cultured Panc-1 cells, including miRNAs miR-21 and miR-
335, PPP1R1B (protein phosphatase1, regulatory subunit1B) and SNED1. Although MDR 
genes and transporter proteins were reported to contribute to chemoresistance in PDAC [226, 
227], we did not observe this type of changes in our 3D model system, on the contrary, we 
found a decreased expression at least for MRP1/ABCC1. Finally and as expected, 
significantly higher chemoresistance was detected in 3D cultured cells upon testing of 
various drugs, including gemcitabine and new designed substances. Interestingly, both 2D 
and 3D cultured Panc-1 cells were sensitive to the anti-metabolites MT100 as well as allicin 
and the flavonoid AXP (genistein isoform), indicating those new drugs may have potential 
effects on pancreatic cancer treatment (see Figure 14). The above findings were then 
validated and confirmed on a mouse cell line, freshly established from the current state-of-
the-art pancreatic cancer mouse model with Kras and p53 mutations in the pancreas.  
 
In summary, this study presented a 3D culture model in PDAC that acquires a more stroma-
rich phenotype and thereby displays a strongly increased chemoresistance. Our data even 
support two of the three mechanisms that are proposed to underlie chemoresistance 
according to the novel hypothesis of cell adhesion mediated drug-resistance (CAM-DR) 
[228]: spheroid formation and matrix/fibronectin production (the third mechanism being 
related to the stroma). Taken together, the switch from 2D to 3D growth affects several 
“hallmarks of cancer” and leads to a more aggressive cancer phenotype [229] (see Figure 
15).  
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Figure 14. Comparison of 
chemoresistance between 
2D and 3D culture using 
multiple cytotoxic 
compounds. Histogram 
summarizing the results 
from viability assays 
performed on 2D and 3D 
Panc-1 cell cultures. 
Different drugs were used 
at the indicated 
concentrations. Data are 
plotted as percentage of the 
respective untreated control 
(CTR) and each drug was 
tested three times in 
octuplets.  
Gem: gemcitabine.  
All: allicin.  
AX: AXP-107-11. 
                                                                                                                                                                                       
 
 
 
 
 
 
                                                                                                                                                                                        
 
Figure 15. Representation of 
the characteristics of the 3D 
spheroid model in relation to the 
holistic hallmarks of cancer 
according to Hanahan and 
Weinberg [229] observed in the 
reductionist pancreatic cancer 
mono-spheroid model. Figure 
15 is adapted from Longati P, 
Jia X, Eimer J, Wagman A, 
Witt MR, Rehnmark S, Verbeke 
C, Toftgård R, Löhr M, Heuchel 
RL: 3D pancreatic carcinoma 
spheroids induce a matrix-
rich, chemoresistant 
phenotype offering a better 
model for drug testing. BMC 
Cancer 2013, 13:95.  
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4.4 Paper IV: 
Correctly oriented and activated pancreatic stellate cells engulfing pancreatic ductal 
adenocarcinoma cells to form an avascular, stroma-containing mini-tumour: 
Establishment of the model and first description. 
By understanding the pivotal role of PSCs in pancreatic cancer progression, metastasis and 
chemoresistance, we aimed to improve the current 3D model of PDAC as the multicellular 
tumour spheroids including ductal epithelial cells and PSCs, which represent the tumour-
stromal interaction characteristic of in vivo solid tumours.  
 
However the development of 3D multicellular tumour spheroids is more complex than cell 
spheroids of single cell type. How to organize heterogeneous cells in spheroids, particularly 
reflecting an in vivo situation of a pancreatic carcinoma was a big challenge of this study. We 
adapted PSCs to non-adhesive growth by a three-month culture on the agarose gel. 
Interestingly such conditioned PSCs (PSC-c) were able to form the hetero-spheroids with 
human pancreatic cancer cells in a novel, unexpected way. The Panc-1/PSC-c hetero-
spheroids grew as firm spheroids with the PSCs in a cortical layer, similar to the patient 
situation, where nests of tumour cells are surrounded by a web of stromal cells (see Figure 
16). Moreover, PSC-c became activated when growing in hetero-spheroids with cancer cells. 
We found that α-SMA and α-vimentin protein, activated PSCs markers, were strongly 
expressed in the outer layer of hetero-spheroids suggestive of the location of PSCs within the 
hetero-spheroids. As expected, higher ACTA2 mRNA levels in hetero-spheroids were 
observed when compared to the same number of PSCs from mono-spheroids. In addition, 
various pancreatic epithelial cells were tested to form hetero-spheroids with PSC-c, including 
human pancreatic tumour cell lines Paca44, the normal human pancreatic ductal epithelial 
cell line HPDE and KPC cells derived from a mouse PDAC model.  
 
To investigate the feature of multicellular PDAC spheroids in the presence of PSCs, we 
compared the expression of genes associated with adhesion, proliferation, ECM and 
chemoresistance between mono- and hetero-spheroids. The mRNA expression of E-
cadherin, an important protein component of tight junctions, was up-regulated in the hetero-
spheroids compared to mono-spheroids. As the dedicated binding partner, E-cadherin and β-
catenin were strongly expressed over the interphase between cancer cells and PSCs in the 
hetero-spheroids. The expression of fibronectin and collagen I was up-regulated in hetero-
spheroids. Particularly, the immunofluorescence staining in hetero-spheroids showed a 
network-like fibronectin expression compared to the more diffuse and homogeneous 
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appearance of fibronectin in mono-spheroids, suggesting that enhanced ECM production in 
hetero-spheroids is similar to the patient situation. In addition, mRNA expression of lumican, 
COX2 and PPP1R1B was up-regulated in hetero-spheroids compared to mono-spheroids, 
which play important roles in collagen fibrillogenesis, cell proliferation and migration, 
metastasis as well as chemoresistance [230-233]. 
 
 
Figure 16. Development of mono- and hetero-spheroids using non-conditioned eGFP-PSC (PSC non-c), 
conditioned eGFP-PSC (PSC-c) and Panc-1 human PDAC cells. Pictures were taken on day1 and day 4. The 
PSC non-c cells are found inside the white, stippled circle, i.e. in the center of the spheroid.  
 
Tumour hypoxia has been known for decades to negatively affect therapy outcome of cancer 
for decades. We applied the hypoxia incubations on mono- and hetero-spheroids and 
investigated the role of hypoxia in our 3D cell culture model. Interestingly, hetero-spheroids 
shrank in the absence of O2 after two-day- or five-day-culture. Moreover, we found ECM 
component fibronectin, stromal marker α-SMA and growth factor PDGF-B were all up-
regulated on the mRNA expression level in hypoxia. In addition, we applied a 6-hour-
incubation of hypoxia on 4-day-spheroids, when spheroids were normally used for drug test 
in our previous study. We found the mRNA expression of hypoxia-inducible genes was 
enhanced, such as PDGF-B, VEGF, GLUT-1, ZEB-1 and LOX (lysyl oxidase), following a 
slightly enhanced HIF-1α mRNA expression. Furthermore, a strong enhancement of gene 
PPP1R1B and cancer stem cell marker CD24, both related to chemoresistance, was found in 
the hetero-spheroids after hypoxia incubations (see Figure 17). Interestingly, we found the 
protein expression of HIF-1α varied in different type of nomoxic spheroids and there was 
even a slightly expressed HIF-1α protein in 2D cultured cells. The 3D cultured Panc-1 cells 
did express HIF-1α protein, but HIF-1α protein was not found in PSC-c mono-spheroids. 
Thus Panc-1/PSC-c spheroids had a lower expression of HIF-1 α protein compared to pure 
Panc-1 mono-spheroids. As a low differentiation PDAC cell line, Panc-1 cells carry both 
KRAS and TP53 mutation. On one hand, HIF-1α protein may be stimulated by oncogenes in 
these cells and thereby expressed HIF-1α in normoxia; on the other hand the specific 3D 
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structure in our PDAC cell spheroids may induce the mild ‘intra-tumour hypoxia’ and 
enhance HIF-1α protein expression in spheroids. Taken together, our data suggest the 
expression of HIF-1α may result in alter the sensitivity of tumour to chemotherapy due to 
increased malignancy and invasiveness of human PDAC.  
 
 
  
 
 
 
 
 
Figure 17. Gene expression analysis in Panc-1/PSC-c spheroids with normoxic and hypoxic incubation using 
qRT-PCR in left and right.  
 
In summary, the 3D hetero-compound spheroid model of pancreatic cancer cells engulfed by 
PSCs represents a valuable model, allowing for the first time to study the interaction and 
mutual dependency of these two principal cell types found in human PDAC in a way more 
close to the patient. Further, it allows high-throughput drug screening on both the stromal 
cells and the tumour cells. And more studies are required to identify the features of our novel 
hetero-compound spheroid model in association with chemoresistance. 
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5 GENERAL CONCLUSIONS 
 Evaluation of the effects of exendin-4 on free and encapsulated islet grafts in a rodent  
model revealed that preculture with exendin-4 followed by recipient treatment improved 
the outcome of both free and macroencapsulated islet grafts due to a larger surviving 
endocrine cell volume.  
 
 Exendin-4 may improve islet graft resistance to hypoxia during the peritransplant period 
by increasing the expression of HIF-1α. 
 
 In PDAC MiaPaCa2 cells, excess glucose increases HIF-1α and ATP in hypoxic wt-
MiapaCa2 cells; however extracellular glucose and hypoxia regulate glucose 
metabolisms independent of HIF-1α. And cell migration is stimulated by glucose via 
both HIF-1α dependent and independent mechanism. 
 
 Development of a high-throughput 3D cell culture drug screening system for pancreatic 
cancer, which displays a strongly increased chemoresistance. 
 
 HIF-1α and its downstream hypoxia-inducible genes are up-regulated in this cell 
spheroid model of pancreatic cancer epithelial cells, which stimulates glycolytic switch 
when cells undergo the transition from 2D to 3D cultures.  
 
 Development of a novel 3D hetero-spheroid model with PSCs in the correct, i.e. outer 
orientation combined with cancer epithelial cells in the center. The expression of genes 
associated with adhesion, proliferation, ECM and chemoresistance was up-regulated.  
 
 HIF-1α expression in the hetero-spheroids of human PDAC is associated with the 
increased ECM production and enhanced expression of gene PPP1R1B (DARP-32) as 
well as cancer stem cell marker (CD24), which might enhance tumour chemoresistance. 
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